Notis Global (NGBL) S-1 9 Apr 15 IPO registration Financial data

Document_and_Entity_Informatio

Document and Entity Information	12 Months Ended
	Dec. 31, 2014
Document And Entity Information [Abstract]
Document Type	S-1
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Trading Symbol	MDBX
Entity Registrant Name	Medbox, Inc.
Entity Central Index Key	1547996
Entity Filer Category	Non-accelerated Filer

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets
Cash and cash equivalents	$101,182	$168,003
Marketable securities	94,776	184,800
Accounts receivable	8,774	339,735
Notes receivable	0	115,000
Inventory	961,236	632,986
Deposits in escrow	400,476	0
Prepaid expenses and other current assets	66,220	89,241
Total current assets	1,632,664	1,529,765
Property and equipment, net of accumulated depreciation of $50,192 and $21,123, respectively	158,318	140,658
Assets held for resale	399,594	0
Investments, at cost	0	1,200,000
Intangible assets, net of accumulated amortization of $83,500 and $32,750 respectively	709,153	682,429
Goodwill	1,260,037	1,090,037
Deposits and other assets	104,726	98,726
Total assets	4,264,492	4,741,615
Current liabilities
Accounts payable	1,713,627	305,934
Accrued interest payable	372,990	0
Accrued expenses	610,444	142,380
Deferred revenue, current	204,091	683,621
Notes payable	261,434	75,000
Related party notes payable	678,877	111,794
Convertible notes payable, net of discount of $1,225,573	2,524,427	0
Derivative Liability	3,691,853	0
Customer deposits	1,525,808	785,861
Total current liabilities	11,583,551	2,104,590
Deferred revenue, less current portion	568,515	0
Deferred tax liability	160,000
Total liabilities	12,312,066	2,104,590
Commitments and Contingencies (Note 19)
Stockholders' Equity/(Deficit)
Preferred stock, $0.001 par value: 10,000,000 authorized; 3,000,000 and 3,000,000 issued and outstanding as of December 31, 2014 and 2013, respectively	3,000	3,000
Common stock, $0.001 par value: 100,000,000 authorized, 30,496,909 and 29,525,750 issued and outstanding as of December 31, 2014 and 2013, respectively	30,497	29,526
Additional paid-in capital	15,315,110	8,156,358
Common stock subscribed	0	-15,000
Treasury stock	-1,209,600	0
Accumulated deficit	-22,078,193	-5,536,859
Accumulated other comprehensive loss	-108,388	0
Total stockholders' equity/(deficit)	-8,047,574	2,637,025
Total liabilities and stockholders' equity/(deficit)	$4,264,492	$4,741,615

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Property and equipment, accumulated depreciation (in Dollars)	$50,192	$21,123
Intangible assets, accumulated amortization (in Dollars)	83,500	32,750
Convertible notes payable, discount	$1,225,573
Preferred stock, par value (in Dollars per share)	$0.00	$0.00
Preferred stock, authorized	10,000,000	10,000,000
Preferred stock, issued	3,000,000	3,000,000
Preferred stock, outstanding	3,000,000	3,000,000
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, authorized	100,000,000	100,000,000
Common stock, issued	30,496,909	29,525,750
Common stock, outstanding	30,496,909	29,525,750

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]
Revenue	$621,106	$2,062,083	$1,176,829
Revenue from related party	75,301	0	0
Less: allowances and refunds	-67,275	0	0
Net revenue	629,132	2,062,083	1,176,829
Cost of revenues	3,796,651	2,660,749	1,051,135
Gross profit/(loss)	-3,167,519	-598,666	125,694
Operating expenses
Selling and marketing	933,627	664,383	806,221
Research and development	242,232	74,861	176,964
General and administrative	9,109,205	2,456,435	895,798
Total operating expenses	10,285,064	3,195,679	1,878,983
Loss from operations	-13,452,583	-3,794,345	-1,753,289
Other income (expense)
Interest income (expense), net	-1,282,761	6,905	-4,948
Change in fair value of derivative liabilities	-1,805,990	0	0
Total other income (expense)	-3,088,751	6,905	-4,948
Loss before provision for income taxes	-16,541,334	-3,787,440	-1,758,237
Provision for income taxes	0	4,000	0
Net loss	-16,541,334	-3,791,440	-1,758,237
Loss per share attributable to common stockholders
Basic (in Dollars per share)	($0.55)	($0.13)	($0.07)
Diluted (in Dollars per share)	($0.55)	($0.13)	($0.07)
Weighted average shares outstanding
Basic (in Shares)	30,067,693	28,971,983	25,119,175
Diluted (in Shares)	30,067,693	28,971,983	25,119,175
Other Comprehensive loss
Net loss	-16,541,334	-3,791,440	-1,758,237
Unrealized loss from marketable securities	-108,388	0	0
Comprehensive loss	($16,649,722)	($3,791,440)	($1,758,237)

CONSOLIDATED_STATEMENT_OF_STOC

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY/(DEFICIT) (USD $)	Total	Preferred Stock [Member]	Common Stock [Member]	Common Stock Subscribed [Member]	Treasury Stock [Member]	Additional Paid-In Capital [Member]	Retained Earnings (Accumulated) (Deficit) [Member]	Accumulated Other Comprehensive Loss [Member]
Balances at Jan. 01, 2012	$310,193	$6,000	$20,830			$270,545	$12,818
Balances (in Shares) at Jan. 01, 2012		6,000,000	20,829,678		0
Issuance of common stock for acquisition PVMI			4,000			-4,000
Issuance of common stock for acquisition PVMI (in Shares)			4,000,000
Buyout of PVMI shareholders	-125,000					-125,000
Issuance of common stock, net of issuance costs	858,415		2,463			855,952
Issuance of common stock, net of issuance costs (in Shares)			2,463,366
Proceeds from common stock subscribed			74			153,176
Proceeds from common stock subscribed (in Shares)			74,100	-153,250
Capital contributions, related parties	561,000					561,000
Unrealized loss from marketable securities	0
Net loss	-1,758,237						-1,758,237
Balances at Dec. 31, 2012	-153,629	6,000	27,367	-153,250		1,711,673	-1,745,419
Balances (in Shares) at Dec. 31, 2012		6,000,000	27,367,144	-153,250
Issuance of common stock, net of issuance costs	4,486,541		2,115			4,484,426
Issuance of common stock, net of issuance costs (in Shares)			2,115,100
Cancellation of preferred stock		-3,000				3,000
Cancellation of preferred stock (in Shares)		-3,000,000
Issuance of shares to settle accounts payable	119,553		44			119,509
Issuance of shares to settle accounts payable, shares			43,506
Proceeds from common stock subscribed				138,250		-138,250
Issuance of warrants for acquisition of Vaporfection	1,166,000					1,166,000
Capital contributions, related parties	810,000					810,000
Unrealized loss from marketable securities	0
Net loss	-3,791,440						-3,791,440
Balances at Dec. 31, 2013	2,637,025	3,000	29,526			8,156,358	-5,536,859
Balances (in Shares) at Dec. 31, 2013		3,000,000	29,525,750	-15,000
Issuance of common stock, net of issuance costs	2,427,859		486			2,427,373
Issuance of common stock, net of issuance costs (in Shares)			485,830
Stock-based compensation	4,415,799		178			4,415,621
Stock-based compensation (in Shares)			178,125
Exercise of warrants			253			-253
Exercise of warrants ( in shares)			252,812
Issuance of shares to settle accounts payable	316,065		54			316,011
Issuance of shares to settle accounts payable, shares			54,392
Proceeds from common stock subscribed	15,000			15,000
Treasury stock	-1,209,600				-1,209,600
Treasury stock (in Shares)					-60,000
Unrealized loss from marketable securities	-108,388							-108,388
Net loss	-16,541,334						-16,541,334
Balances at Dec. 31, 2014	($8,047,574)	$3,000	$30,497		($1,209,600)	$15,315,110	($22,078,193)	($108,388)
Balances (in Shares) at Dec. 31, 2014		3,000,000	30,496,909		-60,000

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities
Net income loss	($16,541,334)	($3,791,440)	($1,758,237)
Adjustments to reconcile net income loss to net cash:
Depreciation and amortization	79,819	69,564	29,922
Gain on the sale of property and equipment	0	-20,682	0
Provisions and allowances	67,275	0	0
Gain on sale of investments and property and equipment	-9,600	0	0
Market value of securities received for services	-203,165	0	0
Change in fair value of derivative liability	1,805,990	0	0
Amortization of debt discount	935,290	0	0
Stock based compensation	4,415,799	0	0
Changes in operating assets and liabilities
Accounts receivable	263,686	518,171	-1,042,000
Inventory	-328,250	-48,180	-316,254
Deposits in escrow	-400,476	0	0
Prepaid expenses and other assets	17,021	-36,725	0
Accounts payables	1,723,759	-393,458	190,668
Accrued interest payable	372,990	0	0
Accrued expenses	468,064	0	0
Customer deposits	924,747	675,762	0
Deferred revenue	88,985	-716,409	1,451,030
Net cash used in operating activities	-6,319,400	-3,743,397	-1,444,871
Cash flows from investing activities
Issuance of note receivable	0	-115,000	0
Receipts on notes receivable, net	115,000	0	104,650
Purchase of property and equipment, net	-46,729	-134,451	0
Purchase of real estate	-399,594	0	0
Purchase of intangible assets, net	-87,474	0	0
Advances for investments	0	-1,250,000	0
Net cash used in (provided by) investing activities	-418,797	-1,499,451	104,650
Cash flows from financing activities
Receipts on advances to officer	0	0	177,050
Contribution from related parties	0	810,000	561,000
Payments on a long term debt	0	-16,307	-15,771
Payments on (proceeds from) notes payable	-75,000	-150,000	50,000
Dividends paid to subsidary's shareholders	0	0	-49,965
Proceeds from (payments on) Related parties notes payable	567,083	-746,285	744,038
Proceeds from issuance of notes payable	261,434	0	0
Proceeds from issuance of common stock, net	2,442,859	4,486,541	858,415
Proceeds from issuance of convertible notes payable, net	3,475,000	0	0
Net cash provided by financing activities	6,671,376	4,383,949	2,324,767
Net decrease (increase) in cash	-66,821	-858,899	984,546
Cash, beginning of period	168,003	1,026,902	42,356
Cash, end of period	101,182	168,003	1,026,902
Supplemental disclosures of cash flow information:
Cash paid for interest	2,834	2,106	4,975
Cash paid for taxes	0	10,851	59,141
Non-cash investing and financing activities:
Marketable securities received for accounts receivable	-184,000	184,800	125,000
Liabilities assumed for Vaporfection	0	73,739	0
Cancellation of preferred stock	0	3,000	0
Treasury stock received for sale of advances on investments	1,200,000		0
Common stock warrants issued for Vaporfection	0	1,166,000	0
Repayments Of Debt [Member]
Non-cash investing and financing activities:
Common stock issued	0	53,500	0
Stock Issued For Accounts Payable [Member]
Non-cash investing and financing activities:
Common stock issued	316,065	119,536	0
Stock Issued For Related Party Notes Payable [Member]
Non-cash investing and financing activities:
Common stock issued	0	0	125,000
PVM International Inc. (PVMI) [Member]
Non-cash investing and financing activities:
Common stock issued	$0	$0	$2,000

BUSINESS_ORGANIZATION_NATURE_O

BUSINESS ORGANIZATION, NATURE OF OPERATIONS	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
BUSINESS ORGANIZATION, NATURE OF OPERATIONS	NOTE 1 – BUSINESS ORGANIZATION, NATURE OF OPERATIONS
	Business Description
	Medbox, Inc. (the “Company”) was incorporated in the state of Nevada on June 16, 1977, originally as Rabatco, Inc., subsequently changing its name on May 12, 2000 to MindfulEye, Inc., and again on August 30, 2011 to Medbox, Inc. Medbox, Inc. provides specialized consulting services to the marijuana industry and sells associated patented products, including its Medbox medical dispensing system and medical vaporization devices. The Company works with clients who seek to enter the medical and cultivation marijuana markets in those states where approved. Medbox offers turnkey solutions that assist with licensing and compliance, site selection, design and permitting, safety and security, along with full build-out and operational oversight. Medbox’s consulting solutions and technology create structure and process for clients and their respective businesses in this rapidly emerging sector. In addition, through its wholly owned subsidiary, Vaporfection International, Inc. (“VII”), the Company sells a line of vaporizer and accessory products online and through distribution partners. The Company is headquartered in West Hollywood, California.
	On December 31, 2011, Medbox, Inc. entered into a Stock Purchase Agreement with PVM International, Inc. (“PVMI”). Pursuant to two separate closings held on January 1, 2012 and December 31, 2012, the Company acquired from PVMI all of the outstanding shares of common stock in (i) Prescription Vending Machines, Inc.,(PVM) (ii) Medicine Dispensing Systems, Inc. (“MDS, Inc.”) (its Arizona subsidiary), and (iii) Medbox, Inc. (its California subsidiary that is currently inactive) (these three listed subsidiaries are hereafter referred to as the “PVMI Named Subsidiaries”), in exchange for two million shares of the Company’s common stock and a $1 million promissory note.
	The transaction between Medbox, Inc. and PVMI was accounted for as a reverse acquisition, where Medbox, Inc. (the legal acquirer) is considered the accounting acquiree and the PVMI Named Subsidiaries (the legal acquiree) are considered the accounting acquirer. The assets and liabilities are transferred at their historical cost with the capital structure of Medbox, Inc. Medbox, Inc. is deemed a continuation of the business of PVMI Named Subsidiaries and the historical financial statements of PVMI Named Subsidiaries are the historical financial statements of Medbox, Inc.
	The Company’s PVM subsidiary was incorporated in the state of California in 2008 and its subsidiary, MDS, Inc. was incorporated in the state of Arizona in 2011.
	On March 22, 2013, the Company entered into a Securities Purchase Agreement with Vapor Systems International, LLC to acquire 100% of the outstanding common stock of VII in exchange for warrants to purchase 260,854 shares of the Company’s common stock. In addition, the Company agreed to provide up to $1,600,000 in working capital to VII at the Company’s sole discretion which included $175,000 paid to the inventor of certain patents including a warrant to purchase 5,000 shares of the Company’s common stock. This transaction was closed in April 2013.
	Medbox, Inc., a Nevada corporation, operates the business directly and through the utilization of 6 operating subsidiaries, as follows:
		•	Prescription Vending Machines, Inc., a California corporation, d/b/a Medicine Dispensing Systems in the State of California (“MDS”), which distributes our Medbox™ product and provides related consulting services described further below.
		•	Vaporfection International, Inc., a Florida corporation through which we distribute our medical vaporizing products and accessories.
		•	Medbox Property Investments, Inc., a California corporation specializing in real property acquisitions and leases for dispensaries and cultivation centers.
		•	MJ Property Investments, Inc., a Washington corporation specializing in real property acquisitions and leases for dispensaries and cultivation centers in the state of Washington.
		•	Medbox Management Services, Inc., a California corporation specializing in providing management oversight and compliance services to state-licensed dispensaries for cultivation, dispensing, and marijuana infused products (MIPS).
		•	Medicine Dispensing Systems, Inc., an Arizona corporation, which distributes our Medbox dispensing system and provides related consulting services in the State of Arizona.
	In order to obtain the license for one of the Company’s clients the Company registered an affiliated nonprofit corporation Allied Patient Care, Inc. in the state of Oregon.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

The consolidated financial statements include the accounts of Medbox, Inc. and its wholly owned subsidiaries, as named in Note 1 above. All intercompany transactions have been eliminated.

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the consolidated financial statements as well as the reported expenses during the reporting periods. The Company’s significant estimates and assumptions include the valuation of the Company’s common stock used in the valuation of goodwill, accounts receivable and note receivable collectability, inventory, advances on investments, the valuation of restricted stock and warrants received from customers, the amortization and recoverability of capitalized patent costs and useful lives of long-lived assets the derivative liability, and income tax expense. Some of these judgments can be subjective and complex, and, consequently, actual results may differ from these estimates. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Actual results could differ from these estimates.

Concentrations of Credit Risk

The Company maintains cash balances at several financial institutions in the Portland, Oregon, Los Angeles, California area and Florida. Accounts at each institution are insured by the Federal Deposit Insurance Corporation up to $250,000. The Company has not experienced any losses in such accounts and periodically evaluates the credit worthiness of the financial institutions and has determined the credit exposure to be negligible.

Three customers, one of which is a related party through the entity’s stock ownership in the Company (customer C) represented 65.1% of the total revenue of $696,407 for the year ended December 31, 2014.

Customer

December 31, 2014

January -

December 31, 2013

January -

December 2014

December 2013

Accounts Receivable

Revenue

Accounts Receivable

Revenue

Amount, $

%

Amount, $

%

Amount, $

%

Amount, $

%

A

$

—

—

%

$

203,165

29.2

%

$

150,000

44.2

%

$

325,000

15.8

%

B

—

—

175,000

25.1

115,200

33.9

—

—

C

—

—

75,301

10.8

—

—

—

—

Subtotal

—

0

453,466

65.1

265,200

78.1

$

325,000

15.8

%

Total

$

8,774

100

%

$

629,132

100

%

$

339,735

100

%

$

2,062,083

100

%

Advertising and Marketing Costs

Advertising and marketing costs are expensed as incurred. The Company incurred advertising and marketing costs of $933,627, $644,383 and $806,221  for the years ended December 31, 2014, 2013 and 2012, respectively.

Research and Development

Research and development expenses are charged to operations as incurred. The Company incurred research and development costs of $242,232, $74,861 and $176,964 for the years ended December 31, 2014 2013 and 2012, respectively.

Fair Value of Financial Instruments

Pursuant to ASC No. 825, Financial Instruments, the Company is required to estimate the fair value of all financial instruments included on its balance sheets. The carrying value of cash, accounts receivable, other receivables, inventory, accounts payable and accrued expenses and notes payable, related party notes payable, customer deposits, provision for customer refunds and short term loans payable approximate their fair value due to the short period to maturity of these instruments. The Company’s marketable securities and related customer deposits require fair value measurement on a recurring basis as the Company has received advance payment of restricted stock in a publicly traded company for contracted services and received warrants for service provided to unrelated third party. The Company has no exposure to gain or loss on the increase or decrease in the value of the marketable securities received as a payment from customer as any shortfall in the ultimate liquidated value of the securities will be supplemented by additional restricted stock from the customer and any liquidation in excess above the Company’s billings will be returned to the customer. The securities received as a payment for services provided will be exposed to gains or losses following their initial evaluation as of the date the revenue was earned.

Warrants and other financial assets received as a payment for the services provided are recorded as “Marketable securities” under the current assets if they are expected to be realized within 12 months. The Company uses the Black-Scholes model to measure the value of the warrants. At each reporting date the Company will reevaluate the value of marketable securities and record any changes in value to other comprehensive income (loss) under “Unrealized gain or losses from marketable securities”.

Unrealized gain or loss from marketable securities occurs in the process of the reevaluation of the warrants or other financial assets after their initial recognition valuation. At each reporting date the Company reevaluates the value of marketable securities and reflects the change in the statement of changes in equity under other comprehensive income (loss).

Embedded derivative – The Company’s convertible notes payable include embedded features that require bifurcation due to a reset provision and are accounted for as a separate embedded derivative (see Note 13). The Company has estimated the fair market value of the embedded derivative of the Notes based on a weighted probability model. The key valuation assumptions used consist of the price of the Company’s stock, a risk free interest rate based on the average yield of a one year Treasury note and expected volatility of the Company’s common stock all as of the measurement dates, and various estimated reset exercise prices allocated by probability. The Company considers these inputs Level 3 assumptions, based on the application of the estimated probability rate being considered an unobservable input.

A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:

Level 1

Quoted prices in active markets for identical assets or liabilities.

Level 2

Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly.

Level 3

Significant unobservable inputs that cannot be corroborated by market data.

The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of the relevant assets and liabilities that are measured at fair value on a recurring basis.

Total

Quoted Prices

Quoted Prices

Significant

in Active

for Similar

Unobservable

Markets for

Assets or

Inputs

Identical

Liabilities in

(Level 3)

Assets or

Active

Liabilities

Markets

(Level 1)

(Level 2)

December 31, 2014

Marketable securities

$

94,776

$

$

$

94,776

Derivative liability

3,691,853

—

—

3,691,853

Total

$

3,786,629

$

$

—

$

3,786,629

Total

Quoted Prices

Quoted Prices

Significant

in Active

for Similar

Unobservable

Markets for

Assets or

Inputs

Identical

Liabilities in

(Level 3)

Assets or

Active

Liabilities

Markets

(Level 1)

(Level 2)

December 31, 2013

Marketable securities

$

184,800

$

184,800

$

—

$

—

Total

$

184,800

$

184,800

$

—

$

—

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis:

For the year ended

December 31, 2014

Total

Beginning balance

$

—

Initial recognition of conversion feature

1,885,863

Change in fair value of conversion feature

1,805,990

Ending balance

$

3,691,853

Revenue Recognition

Our current revenue model consists of the following income streams:

Consulting fee revenues.

Consulting fee revenues. This revenue stream is a consistent component of our current and anticipated future revenues and is negotiated at the time we enter into a contract. In jurisdictions where there is intense competition for a limited number of dispensing or cultivating licenses, we believe the Medbox model, with its incorporated security measures, promotes a distinct advantage in the application selection process for such licenses, especially in the states where an applicant is graded on the ability to demonstrate compliance with applicable law.

Consulting fee revenue is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonable assured. For multi-year contracts with upfront payments made by customers, the upfront payments are recognized over the longer of the contract period or the customer relationship. For contracts that include multiple deliverables such as the build out of customer facilities, the Company recognizes revenue when a milestone is reached in the contract such as securing the location, delivery of dispensing machines or completion of the facility.

Revenues on dispensary unit and vaporizer sales. Medbox machines retail for approximately $50,000 for each machine set (including the POS system). In addition, many consulting contracts bundle the sale of the dispensary units within the scope of deliverables to be provided that might also include location build out costs. Bundling through consulting packages is the most common way that we sell and distribute Medboxes. Gross margins on our tabletop vaporizer sales and accessories are expected to initially average out to a net loss position due to initial higher manufacturing costs prior to implementation of the cost reduction process that we have undertaken. The introduction of our portable miVape product in the second quarter of 2015 is expected to provide a cost effective product with industry standard margins while providing significant value to the customer.

Revenue on dispensary unit sales is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonable assured. For contracts that include multiple deliverables such as the build out of customer facilities, the Company recognizes revenue when a milestone is reached in the contract such as securing the location, delivery of dispensing machines or completion of the facility. The contract terms are broken down in specific milestones with specific attributable revenue to be earned upon successful completion of the milestone terms. (i.e. if a milestone is completing construction on a client dispensary, the condition for the revenue to be recorded is after issuance of a certificate of occupancy for the newly completed facility. The Company will record a specified amount of revenue attributable to this milestone based on the contract). Equipment sales not associated with a consulting contract are recognized as the product is shipped and title passes. Vaporizer sales are recognized as the product is shipped.

Other revenue includes sales of territory rights, sales/leases of management rights of newly awarded dispensary licenses, and sales/leases of management rights of newly acquired dispensary licenses and physical locations. We enter into transactions with clients who are interested in being granted the right to have us engage exclusively with them in certain territories (which we describe as territory rights), operating existing dispensary locations and buying previously issued dispensary licenses. Terms for each deal are varied and the sales arrangements typically include the delivery of our dispensing technology and dispensary location build-out. We will also seek to enter into contracts to assign exclusive management rights we have been granted by licensees under management rights agreements for retail, dispensary, or cultivation centers for which we have facilitated the granting of licenses.

Other revenue is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonable assured. For multi-year contracts with upfront payments made by customers, the upfront payments are recognized over the longer of the contract period or the customer relationship. For contracts that include multiple deliverables such as the build out of customer facilities, the Company recognizes revenue when a milestone is reached in the contract such as securing the location, delivery of dispensing machines or completion of the facility. The contract terms are broken down in specific milestones with specific attributable revenue to be earned upon successful completion of the milestone terms. (i.e. if a milestone is completing construction on a client dispensary, the condition for the revenue to be recorded is after issuance of a certificate of occupancy for the newly completed facility. The Company will record a specified amount of revenue attributable to this milestone based on the contract. Advance payments from clients in advance of work performed are recorded as customer deposits on the balance sheet.

Revenue from referral fees and revenue sharing from real estate transactions with partners. The Company expects to generate revenue from matching its clients with a real estate financing partner to facilitate property purchases and subsequent leasebacks to our clients at a premium to market rates due to the sensitive use (in particular, marijuana retail (sale for recreational purposes)), dispensary (sale for medical purposes) and cultivation (marijuana growth and production of marijuana edibles)

Referral fee and revenue sharing revenue is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonable assured. For multi-year contracts with upfront payments made by customers, the upfront payments are recognized over the longer of the contract period or the customer relationship. If all required deliverables are complete, the referral fee will be recognized when the customer closes on the subject transaction.

Revenue from providing monthly compliance and accountability support to dispensary operators. The Company expects to generate revenue from providing monthly compliance and accountability support to dispensary operators. Such services will entail bi-weekly onsite reviews of client dispensaries to ensure regulatory compliance, transaction and taxation reporting transparency, and adherence to state licensing guidelines for licensing renewal purposes. Fees will vary in each market area. The Company expects to provide such services based upon internal standards we have established which we believe, if properly followed, will greatly aid the location licensee in its compliance with state and local laws concerning operations of the location.

Monthly compliance and accountability support revenue is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonable assured. Revenue is recognized monthly as the services are delivered to clients.

Cost of Revenue

Cost of revenue consists primarily of expenses associated with the delivery and distribution of our products and services. These include expenses related to the manufacture of our dispensary units, construction expense related to the customer dispensary, site selection and establishment of licensing requirements, and consulting expense for the continued management of the dispensary unit build out, server and security equipment, rent expense, energy and bandwidth costs, and support and maintenance costs prior to when the client moves in. We only begin capitalizing costs when we have obtained a license and a site for operation of a customer dispensary or cultivation center. The previously capitalized costs are charged to cost of revenue in the same period that the associated revenue is earned. In the case where it is determined that previously inventoried costs are in excess of the projected net realizable value of the sale of the licenses then the excess cost above net realizable value is written off to cost of revenues. In addition, cost of revenue related to our vaporizer line of products consists of direct procurement cost of the products along with costs associated with order fulfilment, shipping, inventory storage and inventory management costs.

Inventory

Inventory is stated at the lower of cost or market value. Cost is determined on a cost basis that approximates the first-in, first-out (FIFO) method.

Work in process and related capitalized costs includes costs to build out a dispensary in Portland Oregon that is expected to open in the second quarter of 2015. Costs include tenant improvements to the facility, furniture, fixtures and Medbox dispensary units to be used by the licensed operator. It is anticipated this dispensary will be operated by a Medbox licensed operator and revenue and related cost of revenue will be recorded in the statement of operations in the second quarter of 2015.

Basic and Diluted Net Loss Per Share

Basic net income/loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net income per share include the effects of any outstanding options, warrants and other potentially dilutive securities. The Company did not consider any potential common shares in the computation of diluted loss per share for the periods ending December 31, 2014, 2013 and 2012, due to the net loss, as they would have an anti-dilutive effect on EPS.

As of December 31, 2014 and 2013, the Company has 3,000,000 shares of Series A preferred stock outstanding with par value of $0.001 that could be converted into 15,000,000 shares of the Company’s common stock. As of December 31, 2012 there were 6,000,000 shares of Series A preferred stock outstanding, which could be converted into 30,000,000 shares. Additionally the Company has 206,480 warrants to purchase common stock outstanding as of December 31, 2014. The Company also has $3,750,000 in convertible debentures outstanding at December 31, 2014, whose underlying shares were not included as they are convertible at the holders’ option at an initial fixed conversion price of $11.75.

Accounts Receivable and Allowance for Bad Debts

The Company is subject to credit risk as it extends credit to our customers for work performed as specified in individual contracts. The Company extends credit to its customers, mostly on an unsecured basis after performing certain credit analysis. Our typical terms require the customer to pay a portion of the contract price up front and the rest upon certain agreed milestones. The Company’s management periodically reviews the creditworthiness of its customers and provides for probable uncollectible amounts through a charge to operations and a credit to an allowance for doubtful accounts based on our assessment of the current status of individual accounts. Accounts still outstanding after the Company has used reasonable collection efforts are written off through a charge to the allowance for doubtful accounts. As of December 31, 2014 and December 31, 2013, the Company’s management considered all accounts outstanding fully collectible.

Property and Equipment

Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses accelerated depreciation methods for tax purposes where appropriate. The estimated useful lives for significant property and equipment categories are as follows:

Vehicles

5 years

Furniture and Fixtures

5 years

Office equipment

3 years

Assets Held for Resale

During 2014, the Company has entered into various real estate purchase agreements to support the filing of retail dispensary or cultivation facility licenses in certain states and localities. The cost of the acquired real estate is included in Assets Held for Resale on the consolidated balance sheet. The Company intends to sell the real estate to a long term investor after the license is granted. The Company does not depreciate assets held for resale.

Income Taxes

The Company accounts for income taxes under the asset and liability method in accordance with ASC 740. The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred tax assets and liabilities are classified as current and non-current based on their characteristics. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.

In addition, the Company’s management performs an evaluation of all uncertain income tax positions taken or expected to be taken in the course of preparing the Company’s income tax returns to determine whether the income tax positions meet a “more likely than not” standard of being sustained under examination by the applicable taxing authorizes. This evaluation is required to be performed for all open tax years, as defined by the various statutes of limitations, for federal and state purposes.

Commitments and Contingencies

Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and its legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed.

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed.

The Company accrues all legal costs expected to be incurred per event, up to the amount of their deductible.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. Generally Accepted Accounting Principles when it becomes effective. The new standard is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period and is to be applied retrospectively, with early application not permitted. The new standard permits the use of either the retrospective or cumulative effect transition method. We are currently evaluating the effect that ASU 2014-09 will have on our consolidated financial statements and related disclosures. We have not yet selected a transition method nor have we determined the effect of the standard on our ongoing financial reporting.

Management’s Evaluation of Subsequent Events

The Company evaluates events that have occurred after the balance sheet date of December 31, 2014, through the date which the consolidated financial statements were issued. Based upon the review, other than described in Note 20 – Subsequent Events, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements.

Going Concern

The Company recently revised its business model and completed a restatement of its financial statements. The revision to the business model which plans for long term contracts to manage dispensaries or cultivation centers tends to defer revenue and cash flow while expensing the costs to develop markets currently. The recently completed restatements and the on-going investigations by the SEC and the Department of Justice have added general and administrative expenses. The Company also operates in a new, emerging industry where business models are still developing and finalizing new deals can take longer than in more mature industries.

The financial statements were prepared on a going concern basis. The going concern basis assumes that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. During the year ended December 31, 2014, the Company had a net loss of approximately $16.5 million, negative cash flow from operations of $6.3 million and negative working capital of $10.0 million. The Company will need to raise capital in order to fund its operations. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement a business plan. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

As disclosed in our Form 8-K dated January 28, 2015, our lenders have committed to an additional $3.3 million in funding as our annual SEC filings are completed and the Form S-1 filed with the SEC. Due diligence is in process between an investor and our majority shareholder to sell his majority position which would also yield $5 million in new equity capital for the Company over the next 18 months (see Note 20). Management is committed to conducting a road show after the Form S-1 is declared effective to raise additional equity capital in 2015. The Company expects that these plans will provide it the necessary liquidity through the first quarter of 2016.

To address its financing requirements, the Company will seek financing through debt and equity financings. It is uncertain the Company can obtain financing to fund operating deficits until profitability is achieved. This need may be adversely impacted by: uncertain market conditions, approval of sites and licenses by regulatory bodies and adverse operating results. The outcome of these matters cannot be predicted at this time.

ACQUISITION

ACQUISITION	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
ACQUISITION	NOTE 3 – ACQUISITION
	On March 22, 2013, the Company entered into a purchase agreement for 100% of the issued and outstanding common stock of Vaporfection International Inc. (“VII”) owned by Vapor Systems International LLC (“VSI”). The Company closed the transaction on April 1, 2013. The Company issued 260,854 warrants to shareholders of VII allowing them to purchase one (1) share of Medbox common stock at $.001 per share beginning April 1, 2014. These warrants were valued for the Company’s accounting purposes at $4.47 per warrant, determined by the Company’s independent appraiser. In addition, the Company assumed certain liabilities and a 10% convertible note of VII in the aggregate amount of approximately $470,000. The total value of the acquisition was approximately $1,635,000 and the purchase price has been allocated as per the Company’s independent valuation as follows:
	Machinery and equipment	$	70,000
	IP and related technology		287,000
	Amortizable intangible assets:
	Customer contracts and related relationships		314,000
	Trade name, trademark, and domain name		46,000
	Non-compete covenants		23,000
	Goodwill		895,000
	Total assets acquired		1,635,000
	Fair value of liabilities assumed		(469,000	)
	Net fair value	$	1,166,000
	The amortizable intangible assets have useful lives not exceeding ten years. No amounts have been allocated to in-process research and development and $895,000 was originally allocated to Goodwill. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired. From the date of acquisition through March 31, 2014, the purchase price allocation period, the liabilities assumed have been increased by approximately $205,000, as they have been accrued or settled. Accordingly, an additional $10,000 and $195,000 was allocated to Goodwill in the years ended December 31, 2014 and 2013, respectively.
	The warrants included a standard anti-dilution provision, which was triggered by the stock dividend declared on December 18, 2013. On or about September 17, 2014, some but not all of the holders of certain warrants for the Company’s common stock issued in connection with the Company’s 2013 purchase of Vaporfection International, Inc. filed suit against the Company in Circuit Court in Palm Beach County, Florida. There was a dispute as to the adjustment of the exercise price, and the suit was resolved in a settlement agreement dated December 29, 2014, which maintained the anti-dilution adjustment as well as an additional 50,000 warrants being issued to certain of the former VII shareholders. The additional warrants were valued at approximately $280,000, which has been recognized as legal expense in the accompanying consolidated financial statements. The expense was determined using the Black Scholes Merton model, with key valuation assumptions used that consist of the price of the Company’s stock at settlement date, a risk free interest rate based on the average yield of a 3 year Treasury note and expected volatility of the Company’s common stock all as of the measurement date. As of December 31, 2014, 252,812 of the warrants were exercised by the former owners of VII.
	In addition to the above warrants, the purchase agreement and associated consulting contract with the prior management company of the business unit calls for additional shares of common stock to be issued in the event that the performance of the business unit exceeds $11,818,140 of accumulated EBITDA over the subsequent 4 year operating period. The performance payout is contingent upon future events and accordingly the Company has treated the obtainment of that performance provision as being remote and consequently has not assigned any future value to the purchase price.
	The amortizable intangible assets, based on their non-deductibility for tax purposes, gave rise to a deferred tax liability in the amount of $160,000. Goodwill was increased accordingly, the balance after the purchase price allocation adjustments disclosed previously is $1,260,037 at December 31, 2015.
	The Company evaluated Goodwill at year end, and as the Company determined that based on qualitative factors it was not more likely than not that there was not any impairment, they performed Step 1 of the Goodwill impairment test. Since the fair value, based on undiscounted expected future cash flows, was in excess of the units carrying value, the Company concluded no impairment was necessary to recognize as of December 31, 2014.
	The Company evaluated the Intangible assets with definite lives for any indications of impairment and determined that the same cash projections used for the Goodwill impairment test resulted in a conclusion that no impairment of Intangible assets was necessary.

INVESTMENTS

INVESTMENTS	12 Months Ended
	Dec. 31, 2014
Investments Schedule [Abstract]
INVESTMENTS	NOTE 4 – INVESTMENTS
	On February 8, 2013, the Company entered into an agreement with Bio-Tech Medical Software, Inc. (“Bio-Tech”) which would allow the Company to purchase 833,333 shares of common stock, which represented 25% of Bio-Tech’s issued and outstanding shares of common stock, for $1,500,000. The Company advanced $600,000 upon execution of this agreement for the right to purchase with the remaining balance of $900,000 due and payable in installments at various dates by August 25, 2013. On June 26, 2013, the Company notified Bio-Tech that it was canceling the agreement.
	On February 27, 2014, the Company signed a settlement agreement, and in connection therewith, a second amended and restated technology license agreement with Bio-Tech. Pursuant to the second amended and restated technology license agreement, the Company received full licensed right to biometric inventory tracking technology for the term of five years with no additional monies due. All stock transfer between companies was canceled and rescinded.
	On June 5, 2014 the Company entered into a sale agreement with an affiliate company owned by the co-founder of the Company for the sale of all Bio-Tech rights and claims and a contribution for legal costs of $4,800 in exchange for the return of 30,000 shares of the Company’s common stock with a fair value of $604,800, valued at the market price of the Company’s common shares on the date of the agreement. These shares are treated as treasury stock and can be reissued.
	On March 12, 2013, the Company entered into an agreement with three members of MedVend Holdings LLC (“MedVend”) whereby the Company would acquire 50% of their equity interest in MedVend. The purchase price of the equity interest was $4,100,000. The Company paid an advance of $300,000 upon execution of the contract for the right to purchase and another $300,000 was disbursed as an additional investment to MedVend. In May 2013, the three members of MedVend were named in a lawsuit by that entity’s minority shareholders alleging improper conveyance of the three members’ ownership interest in MedVend to the Company. Accordingly, also in May 2013, Medbox filed suit against MedVend and the three members of that entity that were involved in the transaction (Note 19).
	The shares of common stock received for the Bio-Tech and MedVend sales to the affiliate company are recorded as treasury stock at cost of $1,209,600 for 60,000 shares.

INVENTORY

INVENTORY	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
INVENTORY	NOTE 5 – INVENTORY
	Inventory at December 31, 2014 and 2013 consists of the following:
		December 31, 2014		December 31, 2013
	Work in process and related capitalized costs	$	308,867	$	242,488
	Deposits on dispensing machines		325,973		138,423
	Vaporizers and accessories		154,930		193,575
	Dispensing machines		171,466		58,500
	Total inventory, net	$	961,236	$	632,986
	Work in process and related capitalized costs includes costs to build out a dispensary in Portland Oregon that is expected to open in the second quarter of 2015. Costs include tenant improvements to the facility, furniture, fixtures and Medbox dispensary units to be used by the licensed operator. It is anticipated this dispensary will be operated by a Medbox licensed operator and revenue and related cost of revenue will be recorded in the statement of operations in the second quarter of 2015.
	During the year ended December, 31, 2014, the Company wrote down slow moving, older models of vaporizer inventory with a charge to cost of revenue of $329,154. The Company determined there was no obsolete or slow moving inventory as of December 31, 2013 and 2012.

PROPERTY_AND_EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 6 – PROPERTY AND EQUIPMENT
	Property and equipment at December 31, 2014 and 2013 consists of:
	Property and Equipment	December 31, 2014			December 31, 2013
	Office equipment	$	22,421		$	17,192
	Furniture and fixtures		74,404			73,567
	Website development		46,922			46,922
	Product tooling		64,763			24,100
			208,510			161,781
	Less accumulated depreciation		(50,192	)		(21,123	)
	Property and equipment, net	$	158,318		$	140,658
	Product tooling costs are related to the tooling of a new product by VII. These tooling costs are accumulated and capitalized until launch date of the new product which is expected to commence in the second quarter of 2015.
	Depreciation expense for the years ending December 31, 2014, 2013 and 2012 was approximately $29,000, $37,000 and $30,000, respectively.

ASSETS_HELD_FOR_RESALE

ASSETS HELD FOR RESALE	12 Months Ended
	Dec. 31, 2014
Text Block [Abstract]
ASSETS HELD FOR RESALE	NOTE 7 – ASSETS HELD FOR RESALE
	In the course of seeking licenses for new locations, the Company has to enter into real estate purchase agreements in order to secure the sites to be developed for clients’ dispensaries and cultivation centers. The Company intends to close on the real estate where purchase agreements have been signed, or to seek partners to replace the Company on each property purchased. During the second quarter of 2014 one of the Company’s subsidiaries entered into a real estate purchase agreement for a Washington state property. The purchase transaction was closed during the third quarter for a total purchase price of $399,594 partially financed by a promissory note for $249,000. The note bears an interest rate of 12% per year and matures on January 30, 2015. The balance of Assets held for resale as of December 31, 2014 is $399,594. There were no such assets as of December 31, 2013.

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 8 – INTANGIBLE ASSETS
	The Company acquired certain intangible assets with its purchase of 100% of the outstanding common stock of VII on April 1, 2013. The Company accounts for intangible assets acquired in a business combination, if any, under the purchase method of accounting at their estimated fair values at the date of acquisition. Intangibles are either amortized over their estimated lives, if a definite life is determined, or are not amortized if their life is considered indefinite.
	Intangible assets	December 31, 2014			December 31, 2013
	Distributor relationship	$	314,000		$	314,000
	IP/technology/patents		324,653			332,179
	Domain names		131,000			46,000
	Non-compete covenants		23,000			23,000
	Subtotal		792,653			715,179
	Less accumulated amortization		(83,500	)		(32,750	)
	Intangible assets, net	$	709,153		$	682,429
	The estimated useful lives for significant intangible assets are as follows:
	Distributor Relationship		10 years
	Domain Names		10 years
	IP/Technology/Patents		10 years
	Non-Compete covenants		3 years
	The Company’s management has evaluated the intangible assets and does not believe any impairment of intangible assets has occurred as of December 31, 2014 and 2013.

ACCOUNTS_AND_NOTES_RECEIVABLE

ACCOUNTS AND NOTES RECEIVABLE	12 Months Ended
	Dec. 31, 2014
Receivables [Abstract]
ACCOUNTS AND NOTES RECEIVABLE	NOTE 9 – ACCOUNTS AND NOTES RECEIVABLE
	Accounts receivables
	Periodically the Company assesses and reviews the receivables for collectability. As of December 31, 2014 and 2013, the Company’s management considered all outstanding accounts receivables fully collectible.
	During the year ended December 31, 2014, the Company identified $132,640 of accounts receivable and $75,000 in Notes Receivable where management determined that collection was not likely and therefore the Company recognized bad debt expense of $207,640. The Company will continue to make efforts to collect the full value of the various receivables.
	Notes Receivable current
	During December 2013, the Company entered into a multiple advance secured promissory note for $1,000,000 with a Canadian partner. This note is due and payable, together with interest at 5% per annum, on December 10, 2018. As of December 31, 2013 the outstanding balance of this note receivable was $115,000. During 2014 the Company advanced to the Canadian partner an additional $40,000, bringing the total outstanding to $155,000. On October 20, 2014, the note receivable was cancelled and repaid in full, including accrued interest of $6,424.
	During the third quarter of 2014 one of the Company’s clients signed a Note Receivable for $75,000 as a payment on accounts receivable, with a maturity date of December 31, 2014. However, at December 31, 2014 management determined that collection was not likely, and recognized bad debt expense of $75,000 in connection with the Note Receivable.
	Periodically the Company assesses and reviews the Notes Receivable for collectability. As of December 31, 2013, the Company’s management considered all remaining accounts outstanding fully collectible.

MARKETABLE_SECURITIES

MARKETABLE SECURITIES	12 Months Ended
	Dec. 31, 2014
Investments, Debt and Equity Securities [Abstract]
MARKETABLE SECURITIES	NOTE 10 – MARKETABLE SECURITIES
	Marketable securities of the Company represent the shares received as a payment from clients for services provided.
	Marketable securities	Value as of		Value as of
		December 31, 2014		December 31, 2013
	Shares received as a payment from client	$	—	$	184,800
	Securities from MJ Holdings, Inc.		94,776		—
	Total marketable securities	$	94,776	$	184,800
	On September 5, 2014 the Company received as a deposit 7,000,000 restricted shares in a publicly traded entity, currently called Endocan, as payment for $300,000 in accounts receivable billed to a customer. The restriction on the shares lapsed in 2014. The value of these unliquidated shares was held as collateral against the outstanding amounts owed to the Company up to $300,000 (the value of receivable of the client) until such time that the shares are liquidated and only at the time that the cash proceeds are used to pay off the receivable will any excess cash received be returned to the client in accordance with the contract. The fair value of the shares as of December 31, 2013 (with 12% restricted stock discount as of December 31, 2013) was $184,800. At December 31, 2014 the Company evaluated the shares for impairment, and noted that Endocan is not currently making material information publicly available, is delinquent on their SEC filings, and is thinly traded on the OTC pink sheets. Furthermore, the last filed financial statements show minimal assets and liabilities of over $1,000,000. Management concluded these factors were indications of impairment, and determined the shares were fully impaired, with the decline being other-than-temporary. As the shares were being held as a deposit against the receivable balance, the fair value was also recognized as a customer deposit, and the impairment will therefore fully reduce the related customer deposit, and not be recognized as an impairment expense.
	On May 19, 2014 the Company entered into an agreement with MJ Holdings, Inc., a publicly traded company that provides real estate financing and related solutions to licensed marijuana operators. The Company will market MJ Holdings’ real estate financial products and offerings to its consulting clients and will direct all incoming real estate related opportunities to MJ Holdings. Under the agreement, the Company will receive 50% of management fees and profits realized from the real estate opportunities it presents, in addition to warrants to purchase shares in MJ Holdings. The initial term of the agreement was six months which could have been extended on a month to month basis, but the agreement was terminated at the end of the six month term. MJ Holdings, Inc. agreed to issue to the Company, for this six month term of the contract, 33,333 warrants to purchase common stock on each month’s anniversary of the contract. As of December 31, 2014 the Company received six tranches of warrants for the services provided under the agreement. The following table represents the initial recognition value and subsequent adjustment as of reporting date:
	Warrants	Initial Fair		Fair Value at			Gain or (Loss)			Fair Value as of
		Value		Conversion						December 31,
										2014
	Warrant #1	$	95,866	$	(94,719	)	$	(1,147	)	$	—
	Warrant #2		2,666					5,513			8,179
	Warrant #3		53,867					(44,947	)		8,920
	Warrant #4		30,600					(20,282	)		10,318
	Warrant #5		7,133					12,920			20,053
	Warrant #6		13,033					12,623			25,656
	Total	$	203,165	$	(94,719	)	$	(35,320	)	$	73,126
	At initial recognition the value of warrants is recorded as “Marketable securities” and “Revenue” for services provided. Subsequent to initial recognition all valuation adjustments are reflected through other comprehensive income (loss) as “Unrealized gain or losses from marketable securities”. In June 2014, Warrant #1 was converted to 10,825 shares of MJ Holdings common stock through the cashless exercise option. The fair value of the shares as of December 31, 2014 was $21,650, which represents a $73,069 unrealized loss on marketable securities. The Company uses the published closing price of the stock to value the stock held by the Company.
	The Company uses a Black-Scholes model to measure the value of the warrants. The following assumptions were used by the Company for the Black-Scholes model valuation of the warrants as of their initial valuation:
	Black-Scholes Calculator Data	Initial Valuation and Recognition
		#1		#2			#3			#4		#5		#6
	Warrant
	Stock price, $		8.69		4			8			6.15		2.01		2.02
	Exercise price, $		6.42		8.45			7.87			6.95		3.53		2.56
	Time to maturity, Years		0.5		0.5			0.5			0.5		1		1
	Annual risk-free rate, %		0.05		0.05			0.05			0.05		0.04		0.11
	Annualized volatility, %		70		70			70			70		70		70
	Black-Scholes Value per warrant, $		2.876		0.08			1.616			0.918		0.214		0.391
	Number of warrants/shares		33,333		33,333			33,333			33,333		33,333		33,333
	Total value of warrants/shares, $		95,866		2,666			53,867			30,600		7,133		13,033
	The following data were used by the Company for the Black-Scholes model valuation of the warrants as of December 31, 2014:
	Fair Value of Warrants	As of December 31, 2014
		#2		#3			#4			#5		#6
	Warrant
	Stock price, $		2		2			2			2		2
	Exercise price, $		8.45		7.87			6.95			3.53		2.56
	Time to maturity, Years		1		1			1			1		1
	Annual risk-free rate, %		0.22		0.22			0.22			0.22		0.22
	Annualized volatility, %		120		120			120			120		120
	Black-Scholes Value per warrant, $		0.25		0.27			0.31			0.6		0.77
	Number of warrants/shares		33,333		33,333			33,333			33,333		33,333
	Total value of warrants/shares, $		8,179		8,920			10,318			20,053		25,656

CUSTOMER_DEPOSITS

CUSTOMER DEPOSITS	12 Months Ended
	Dec. 31, 2014
Banking and Thrift [Abstract]
CUSTOMER DEPOSITS	NOTE 11 – CUSTOMER DEPOSITS
	Advance payments from customers are recorded as customer deposits on the consolidated balance sheet.
	Customer deposits	December 31, 2014		December 31, 2013
	Advance payments from customers	$	1,450,770	$	710,225
	Advance payments for vaporizers		75,038		75,636
	Total customer deposits	$	1,525,808	$	785,861

SHORTTERM_DEBT

SHORT-TERM DEBT	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
SHORT-TERM DEBT	NOTE 12 – SHORT-TERM DEBT
	On July 28, 2014 one of the Company’s subsidiaries executed a promissory note for $249,000 for the purchase of real estate (also see Note 7). The note matures on January 30, 2015 and bears 12.0% interest annually. The interest is payable monthly starting August 1, 2014 with a final, sixth payment on January 1, 2015. In the event of a default, as defined, the interest rate increases to 18%, there is a one time 5% late charge on the principal balance, and the note can be accelerated. Subsequent to December 31, 2014, the Company was in default of the repayment terms, and the note terms were modified. (see Note 20).
	The other portion of the notes payable balance represents the outstanding balance in the amount of $12,434 for product liability insurance. The financing of product liability insurance bears 5.99% interest and is payable in monthly payments of $2,524 for nine months with the first payment due on September 5, 2014 and the last payment due on May 5, 2015.
	The notes payable to related parties bear no interest.
	The December 31, 2013 balance of the $75,000 note payable to an unrelated third party was paid in full during 2014.

CONVERTIBLE_NOTES_PAYABLE_AND_

CONVERTIBLE NOTES PAYABLE AND DERIVATIVE LIABILITY	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
CONVERTIBLE NOTES PAYABLE AND DERIVATIVE LIABILITY	NOTE 13 – CONVERTIBLE NOTES PAYABLE AND DERIVATIVE LIABILITY
	On July 21, 2014, as amended on September 19, 2014 and October 20, 2014, the Company entered into a Securities Purchase Agreement whereby the Company agreed to issue convertible debentures (“July 2014 Purchase Agreement Debentures”) in the aggregate principal amount of $3,500,000, in five tranches. The initial closing in the aggregate principal amount of $1,000,000 occurred on July 21, 2014. The second closing in the amount of $1,000,000 occurred on August 26, 2014; the third of $500,000 on September 26, 2014; and the fourth of $250,000 on November 24, 2014. The fifth closing was modified in January, 2015 (See Note 20). The July 2014 Purchase Agreement Debentures bear interest at the rate of 10% per year. The debt is due July 21, 2015, with repayment, including accrued principal and accrued interest, beginning on the eleventh day of the fourth month after issuance and will continue on the eleventh day of each following 8 successive months thereafter.
	Also on September 19, 2014, as amended on October 20, 2014, the Company entered into a securities purchase agreement pursuant to which it agreed to issue convertible debentures (“September 2014 Purchase Agreement Debentures”) (collectively the “Notes”) in the aggregate principal amount of $2,500,000, in two tranches. The initial closing in the principal amount of $1,000,000 occurred on September 19, 2014. The second closing, of $1,500,000, is to occur within 2 days of the effective date of the registration statement filed by the Company for the resale of the shares of common stock issuable upon conversion of the September 2014 Purchase Agreement Debentures. The September 2014 Purchase Agreement Debentures bear interest at the rate of 5% per year. The debt is due September 19, 2015, with repayment, including accrued principal and accrued interest, due in nine monthly installments, commencing the fourth month after issuance.
	Both the July 2014 Purchase Agreement Debentures and September 2014 Purchase Agreement Debentures, share the following significant terms:
	Conversion – All amounts are convertible at any time, in whole or in part, at the option of the holders into shares of the Company’s common stock at a conversion price, or Fixed Conversion Price, which is subject to adjustment as described below.
	The Notes are initially convertible into shares of the Company’s common stock at the initial Fixed Conversion Price of $11.75 per share. The Fixed Conversion Price is subject to adjustment for stock splits, combinations or similar events. If the Company makes any subsequent equity sales (subject to certain exceptions), under which an effective price per share that is lower than the Fixed Conversion Price, then the conversion price will be reduced to equal such price. The July 2014 Securities Purchase Agreement exempts any sales pursuant to the September 2014 Purchase Agreement Debentures from the July 2014 Purchase Agreement Debentures conversion price adjustments.
	Beginning four months (as subsequently amended) after the initial closing, the Company will begin making amortization payments on the debt in cash, prompting a 30% premium or, at their option and subject to certain conditions, in shares of common stock valued at 70% of the lowest volume weighted average price of the common stock for the 20 prior trading days. However, in the event the registration statement filed by the Company in connection with the respective purchase agreements is not effective within 120 days of the initial closing date under the July 2014 Purchase Agreement and 120 days of the initial closing date under the September 2014 Purchase Agreement, the July 2014 Purchase Agreement Debentures’ and the September 2014 Purchase Agreement Debentures’, respectively, conversion rate will be, during the period commencing 120 days after the initial closing date until the registration statement is effective, equal to 63% of the lowest volume weighted average price of the common stock for the 20 prior trading days. If the aforementioned registration statement is not effective within 160 days of the initial closing date, each of the debentures’ conversion rate will be, during the period commencing 160 days after the initial closing date until the registration statement is effective, equal to 60% of the lowest volume weighted average price of the common stock for the 20 prior trading days.
	In connection with each of the purchase agreements, the Company entered into a registration rights agreement with the respective investors, pursuant to which the Company agreed to file a registration statement for the resale of the shares of common stock issuable upon conversion of, or payable as principal and interest on, the respective debentures, within 45 days of the initial closing date under each agreement, and to have such registration statements declared effective within 120 days of the initial closing dates of each purchase agreement. The registration statement was not declared effective within 120 days, and the amortization payment conversion rate was adjusted accordingly.
	The $3,750,000 million principal amount of the Notes were issued net of $275,000 debt discount. The conversion feature of the notes meets the definition of a derivative under ASC 815 and due to the reset provision upon subsequent sales of securities at a price lower than the fixed conversion price, requires bifurcation and is accounted for as a derivative liability. The derivative was initially recognized at its estimated fair value of $1.885 million and created a discount on the Notes that will be amortized over the life of the Notes using the effective interest rate method. The fair value of the embedded derivative will be measured and recorded at fair value each subsequent reporting period and changes in fair value will be recognized in the statement of operations as a gain or loss on derivative. For the year ended December 31, 2014 the Company recognized a loss on the change in fair value of derivative liabilities of $1,805,990. See Note 2 Fair value measure for additional information on the fair value and gains or losses on the embedded derivative.
	As a result of a new convertible debentures loan agreements entered into in January 2015 (Note 20), which include a conversion rate equal to the lower of (a) $5.00 or (b) 51% of the lowest VWAP for the 20 consecutive Trading Days ending on the Trading Day that is immediately prior to the applicable Conversion Date, the reset provision terms of the July 2014 and September 2014 convertible debentures were triggered and the original fixed conversion price were adjusted accordingly.

PREPAID_EXPENSES_AND_OTHER_CUR

PREPAID EXPENSES AND OTHER CURRENT ASSETS	12 Months Ended
	Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	NOTE 14 – PREPAID EXPENSES AND OTHER CURRENT ASSETS
	Prepaid expenses and other currents assets consisted of:
		December 31,		December 31,
		2014		2013
	Rent	$	—	$	3,962
	Directors & officers insurance		31,491		—
	Professional fees		10,000		52,739
	Other vendors		24,729		32,540
	Prepaid expenses and other current assets	$	66,220	$	89,241
	Deposits in escrow
	Deposits in escrow consist of amounts paid to open escrow accounts for the purchase of multiple properties to be used to develop retail dispensary or product cultivation facilities.

RESTRICTED_STOCK_AND_RESTRICTE

RESTRICTED STOCK AND RESTRICTED STOCK UNITS ("RSUs")	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
RESTRICTED STOCK AND RESTRICTED STOCK UNITS ("RSUs")	NOTE 15 – RESTRICTED STOCK AND RESTRICTED STOCK UNITS (“RSUs”)
	On July 23, 2014, in connection with the election of a new Chairman, President and CEO, the Company entered into a two year employment contract with the new CEO. Under the employment contract, the CEO received an award of RSU’s, to be issued within 90 days of the effective date of the Employment Agreement, under the Equity Incentive Plan adopted by the Company, in the amount of the greater (by value) of 50,000 shares of common stock or $500,000 of common stock based on the volume weighted average price for the 30 day period prior to the date of the grant. In October the Company granted 50,000 RSUs in accordance with the employee contract. The Company also agreed to make an equal stock award to the CEO on each anniversary date of the employment agreement. The RSU’s vest immediately during each year of the employment contract. During the third quarter of 2014, 20,000 additional shares were approved to increase the CEO’s first year RSU grant from 50,000 RSU’s to 70,000 RSU’s (see Note 16 for a more detailed discussion of the additional grant). As of December 31, 2014, the fair value of the grant was approximately $970,000 which is being amortized over the CEO’s one year service period.
	On August 21, 2014, the Compensation Committee of the Board of Directors granted Restricted Stock and RSU’s to two Board members who were elected to the Board on April 9, 2014. Under the award, the Directors received 346,875 shares of restricted stock and 121,875 RSU’s under which the holders have the right to receive 121,875 shares of common stock. The grant date fair value of the restricted stock was $3,607,500 and the grant date fair value of the RSU’s was $1,267,500. The restricted Stock and RSU’s vest over the remaining first year of the new Board members’ term ending on March 31, 2015. The fair value of the grant is being amortized over the period from the date of grant, August 21, 2014 to the end of the first year of the Board members’ term, March 31, 2015. Under the Board members’ contracts, additional grants will be made for the second year of the contract.
	During October 2014 the Compensation Committee of the Board of Directors granted 19,452 RSU’s to a new Board member who was elected to the Board on October 22, 2014. The Board member’s contract calls for grants of 100,000 RSU’s for each succeeding year of service beginning on April 1, 2015, which vest quarterly.
	A summary of the activity related to restricted stock and RSUs for the year ended December 31, 2014 is presented below:
	Restricted stock	Total shares			Grant date fair
					value
	Restricted stock non-vested at January 1, 2014		—		$	—
	Restricted stock granted		346,875			10.4
	Restricted stock vested		(178,125	)		10.4
	Restricted stock forfeited		—			—
	Restricted stock non-vested at December 31, 2014		168,750		$	10.4
	Restricted stock units (RSU’s)	Total shares			Grant date fair
					value
	Restricted stock non-vested at January 1, 2014		—		$	—
	Restricted stock granted		422,980			10.84
	Restricted stock vested		(223,396	)		11.19
	Restricted stock forfeited		—			—
	Restricted stock non-vested at December 31, 2014		199,584		$	10.7
	A summary of the expense related to restricted stock and RSUs for the year ended December 31, 2014 is presented below:
	Summary of the expense related to Restricted Stock and RSUs	Year ended
		December 31, 2014
	Restricted Stock	$	663,262
	RSU’s		3,752,537
		$	4,415,799
	There were not any restricted stock or RSU activity in the year ended December 31, 2013.

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 16 – RELATED PARTY TRANSACTIONS
	The aggregate amount of outstanding payables to related parties as of December 31, 2014 and 2013 was $678,877 and $111,794, respectively.
	During 2012, the Company issued notes payable to a shareholder in the aggregate amount of $125,000 in exchange for the shareholder’s original investment in PVM common stock. The notes bear no interest and are due on demand. As of December 31, 2012, the outstanding balance on the notes was $94,000 and as of December 31, 2013, the notes were paid in full.
	On January 1, 2012, the Company issued a note payable to PVMI which is 100% owned by the founder of the Company in the amount of $1,000,000 along with the issuance of 4,000,000 shares of the Company’s common stock for 100% of PVMI Named Subsidiaries and for the exclusive use of patents related to PVMI’s dispensing systems. The note was secured with 1,000,000 shares of the Company’s common stock. The note was due on demand and bore interest at 10% of the outstanding balance beginning January 1, 2013. The balance at December 31, 2012 was $775,038 and as of December 31, 2013, the note was paid in full.
	The Company utilizes Kind Clinics, LLC, which is 100% owned by the former Chief Executive Officer of the Company, Dr, Bruce Bedrick, for management advisory and consulting services. During the year ended December 31, 2012, the Company incurred $113,613 in fees for these services.
	For the year ended December 31, 2012 the Company utilized AVT, Inc., for the procurement, manufacture and assembly of its dispensary units. During 2012, the Company incurred approximately $480,000 and $510,000 in manufacturing costs. In addition, the Company’s existing inventory of dispensary units was held at AVT, Inc.’s manufacturing facility in Corona, California on behalf of the Company. The Company believes that its transactions with AVT, Inc. during 2012 were completed on an arms-length basis.
	The Company utilizes Vincent Chase Inc., which is a related party and 100% owned by a co-founder of the Company for management advisory and consulting services. During the years ended December 31, 2014, 2013 and 2012, the Company incurred fees of $168,625, $262,500 and $230,706, respectively, for these services. The contract for the aforementioned services was terminated on December 8, 2014.
	During 2013, the Company issued two promissory notes payable to Vincent Chase Inc., on September 20, 2013, in the amount of $150,000 and on October 28, 2013 in the amount of $100,000. At December 31, 2013, the outstanding amount for the combined notes was $111,794. These notes were repaid in full during 2014.
	During the year ended December 31, 2014, the Company issued four notes payable to PVM International Inc. (“PVMI”), a related party which is 100% owned by a co-founder of the Company, in the amounts of $250,000, $100,000, $500,000, and $375,000. These notes were subsequently partially repaid leaving $388,477 outstanding as of December 31, 2014. On October 17, 2014 the Company entered into an assignment agreement with PVMI through which PVMI assigned all rights and titles for any opened escrow on real estate purchase agreements in San Diego in exchange for a related party notes payable from the Company. As of the signing date the agreement was valued at $190,400 which represented the value of escrow deposits paid by PVMI for eight different real estate agreements.
	On July 21, 2014, the Company also paid $75,000 to PVMI as a partial payment for advances made by PVMI for escrow deposits used to secure properties for possible license acquisition in the San Diego market area.
	On August 15, 2014, the Company issued a note payable to Vincent Chase, Inc., in the amount of $100,000.
	The notes bear no interest and are payable on demand.
	The Company utilized Dr. Bruce Consulting which is a related party and 100% owned by one of Company’s major shareholders and former Chief Executive Officer for management consulting and advisory service. During the year ended December 31, 2014, the Company incurred expenses in the amount of $43,750 for consulting and advisory services to Dr. Bruce Consulting. For the year ending December 31, 2013, the Company paid salary to Dr. Bruce Bedrick, the former Chief Executive Officer in the gross amount of $133,991.
	During the application process for dispensaries and cultivation centers in Illinois, which took place in September, 2014, Dr. Bruce Bedrick, a major shareholder, provided funding to the applicant entity in the amount of $500,000. This amount was returned by the applicant entity to Dr. Bruce Bedrick by September 30, 2014.
	During the third quarter of 2014, the CEO of the Company and the Chairman of the Board, Mr. Guy Marsala received 20,000 shares from the founder and major shareholder of the Company out of his personal holdings to compensate for his superior performance. On October 24, 2014 the Compensation Committee of the Board of Directors recommended that shares be returned to the founder and issued by the Company as part of the yearly RSU grant. In November 2014, Mr. Marsala returned 20,000 shares to founder and major shareholder and 20,000 additional shares were approved to increase Mr. Marsala’s first year RSU grant from 50,000 RSU’s to 70,000 RSU’s.
	Related parties contributed $810,000 and $561,000 in 2013 and 2012, respectively, to provide funding for growth for the Company. During the first quarter of 2014, the Company completed a contract with a related party and shareholder in the amount of $400,000 which was recognized as a Customer deposit in the Company’s balance
	sheet. In addition, the same related party paid the Company $150,000 for an amount owed to the Company by an unrelated third party to facilitate development at an existing dispensary where the unrelated party purchased an interest during the period. In addition on March 28, 2014 the Company entered into an agreement with a related party for territory rights in Colorado for $500,000. The agreement has a term of five years and in accordance with the Company’s revenue policy, the revenue will be recognized over the five year term.
	During the third quarter of 2014, the Company created the following affiliated entities in connection with license applications: A. Hanna Growers, Inc., Herbal Choice of Illinois, Inc., Nature’s Treatment of Illinois, Inc., Green Blossom of Illinois, Inc., Midwestern Compassionate Care of Illinois, Inc., Midwestern Wellness Group of Illinois, Inc., Green Blossom, Inc., Nature’s Treatment, Inc. and Herbal Choice, Inc.

STOCKHOLDERS_EQUITY

STOCKHOLDER'S EQUITY	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
STOCKHOLDER'S EQUITY	NOTE 17 – STOCKHOLDER’S EQUITY
	Preferred Stock
	In November 2011, the Company issued 6,000,000 shares of $0.001 par value Series A convertible preferred stock to the founder and a shareholder of the Company. This preferred stock can be converted to common stock at a ratio of 1 (one) share of Series A Preferred Stock to 5 (five) shares of common stock. In October 2012, 3,000,000 shares of Series A Preferred Stock were returned to the Company by the shareholder and reissued to the founder. In January 2013, the founder returned to the Company the 3,000,000 shares of Series A Preferred Stock and they were immediately cancelled. As of September 30, 2014, there are 3,000,000 shares of Series A Preferred Stock outstanding.
	The Series A Preferred Stock has special voting rights when voting as a class with the Common Stock as follows: (i) the holders of Series A Preferred Stock shall have such number of votes as is determined by multiplying (a) the number of shares of Series A Preferred Stock held by such holder, (b) the number of issued and outstanding shares of the Corporation’s Series A Preferred Stock and Common Stock (collectively, the “Common Stock”) on a Fully-Diluted Basis (as hereinafter defined), as of the record date for the vote, or, if no such record date is established, as of the date such vote is taken or any written consent of stockholders is solicited, and (c) 0.00000025; and (ii) the holders of Common Stock shall have one vote per share of Common Stock held as of such date. “Fully-Diluted Basis” mean that the total number of issued and outstanding shares of the Company’s Common Stock shall be calculated to include (a) the shares of Common Stock issuable upon exercise and/or conversion of all of the following securities (collectively, “Common Stock Equivalents”): all outstanding (a) securities convertible into or exchangeable for Common Stock, whether or not then convertible or exchangeable (collectively, “Convertible Securities”), (b) subscriptions, rights, options and warrants to purchase shares of Common Stock, whether or not then exercisable (collectively, “Options”), and (c) securities convertible into or exchangeable or exercisable for Options or Convertible Securities and any such underlying Options and/or Convertible Securities.
	Common Stock
	On June 5, 2014 the Company entered into two separate sales agreements with an affiliate company owned by the co-founder of the Company. The first was for the sale of all of the Company’s Bio-Tech rights and claims, as consideration for which the Company received 30,000 shares of the Company’s common stock with a fair value of $604,800, as based on the market price of the common stock. The second was for the sale of all the MedVend rights and claims in exchange for 30,000 shares of the Company’s common stock, with a fair value of $604,800 as based on the market price of the common stock. These 60,000 shares of common stock received back by the Company are treated as treasury stock and can be reissued.
	During January, 2014, the Company issued 485,830 shares of its common stock at the price of $5.00 per share, resulting in net cash proceeds of $2,427,859.
	On December 18, 2013 the Company declared a two-for-one (2:1) forward stock split on its outstanding common stock, effectuated in the form of a common stock dividend. The stock dividend, aggregating in 14,762,875 common shares, was issued on and announced by the Financial Industry Regulatory Authority (FINRA) on February 3, 2014. Accordingly, the Company’s consolidated financial statements have been retroactively stated for all periods presented to reflect the 2:1 forward stock split.
	On September 8, 2014 the Company issued 93,751 shares of common stock to two board members from a total grant of 346,875 awarded by the Compensation Committee to board members. On October 7, 2014 additional 84,374 shares were issued to the same board members.
	During the fourth quarter of 2014 the Company issued 52,892 shares of its common stock, valued at $316,065 as based on the market price of the common stock, as a payment of certain accounts payables.
	During 2013, the Company issued 2,115,100 shares of common stock at an average price $2.23, resulting in net cash proceeds of $4,486,541. In addition, during 2013, the Company had non-cash additions to equity from the issuances of warrants and common stock in connection with the VII acquisition of $1,285,553.
	During 2012, the Company sold approximately 2,463,000 shares of common stock for proceeds of approximately $858,000. The balance of $153,250 for the remaining 74,100 shares is to be received in 2013.
	On January 1, 2012, the Company issued 4,000,000 shares of the Company’s common stock as consideration for 100% of certain named subsidiaries PVMI, a related party, and for the exclusive use of patents related to PVMI’s dispensing systems. (see Note 16)

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 18 – INCOME TAXES
	The Company accounts for income taxes under FASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recorded based on the differences between the tax basis of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences.
	Deferred income taxes are provided for temporary differences arising from using the straight-line depreciation method for financial statement purposes and accelerated methods of depreciation for income taxes, including differences between book and tax for amortizing organization expenses. In addition, deferred income taxes are recognized for certain expense accruals, allowances and net operating loss carry forwards available to offset future taxable income, net of valuation allowances for potential expiration and other contingencies that could impact the Company’s ability to recognize the benefit.
	The Company is required to file federal and state income tax returns. Various taxing authorities may periodically audit the Company’s income tax returns. These audits would include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions.
	The Company is in the process of an examination by the Internal Revenue Service of the year ended December 31, 2011.
	Management has performed its evaluation of all other income tax positions taken on all open income tax returns and has determined that there were no positions taken that do not meet the “more likely than not” standard. Accordingly, there are no provisions for income taxes, penalties or interest receivable or payable relating to uncertain income tax provisions in the accompanying consolidated financial statements.
	From time to time, the Company may be subject to interest and penalties assessed by various taxing authorities. These amounts have historically been insignificant and are classified as other expenses when they occur.
	Deferred tax assets and liabilities result from temporary differences in the recognition of income and expense for tax and financial reporting purposes. Significant components of the Company’s deferred tax assets and liabilities are as follows at December 31:
		2014			2013
	Deferred tax assets:
	Customer deposits	$	295,000		$	293,000
	Deferred revenue		35,000
	Share based compensation		1,760,000
	NOL carryforward		5,400,000			2,377,000
	Total deferred tax asset		7,490,000			2,670,000
	Deferred tax liabilities:
	Deferred revenue		—			285,000
	Intangible asset amortization		20,000
			20,000			285,000
			7,470,000			2,385,000
	Less: Valuation allowance		(7,470,000	)		(2,385,000	)
		$	—		$	—
	A valuation allowance has been recorded against the realizability of the net deferred tax asset such that no value is recorded for the asset in the accompanying consolidated financial statements. The valuation allowance increased $5,085,000 between the year ended December 31, 2014 and 2013.
	The Company has net operating loss carryforwards available for federal and state tax purposes of approximately $13,510,000, at December 31, 2014, which expire in varying amounts through 2034.
	For the years ended December 31, 2014, 2013 and 2012, a reconciliation of the statutory rate and effective rate for the provisions for income taxes consists of the following:
		2014			2013			2012
	Federal Tax statutory rate		34	%		34	%		34	%
	State tax statutory rate		6	%		8.84	%		8.84	%
	Permanent differences		(6.72	)%		—	%
	Valuation allowance		(33.28	)%		(42.84	)%		(42.84	)%
	Effective rate		0	%		0	%		0	%

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 19 – COMMITMENTS AND CONTINGENCIES
	The Company leases property for its day to day operations and has recently begun leasing facilities for possible retail dispensary locations and cultivation locations as part of the process of applying for retail dispensary and cultivation licenses.
	Office Leases
	On August 1, 2011, the Company entered into a lease agreement for office space located in West Hollywood, California through June 30, 2017 at a monthly rate of $14,397. Starting July 1, 2014, the monthly rent increased by 3% to $14,828 per month.
	In addition, the Company leased office facilities located at West Hills, California and Scottsdale, Arizona from unrelated third parties at a monthly rate of $1,300 and $1,420. The West Hills lease was on a month to month basis. The Arizona lease was a non-auto renewing lease with the most current agreement covering the period from May 1, 2014 to October 31, 2014. The Arizona lease term expired on October 31, 2014. The Company terminated the West Hills and Scottsdale leases effective November 1, 2014.
	On December 17, 2013 the Company’s subsidiary Vaporfection International Inc. entered into a 1 year non-cancelable office lease in Deerfield Beach, Florida. The lease started on January 1, 2014 at a monthly rate of $1,981. As of December 31, 2014 this lease was terminated.
	The Company rents virtual offices/meeting spaces in Seattle and Illinois on a month to month basis for an aggregate of approximately $705 per month. The payment is charged to rent expense as incurred.
	Total rent expense under operating leases for the year ended December 31, 2014, 2013 and 2012, was $ 204,726, $139,330 and $124,727, respectively
	Retail/Cultivation facility leases
	The Company’s business model of acquiring retail dispensary and cultivation licenses has made it important to acquire real estate either through lease arrangements or through purchase agreements in order to secure a possible license. On May 8, 2014, the Company entered into a lease agreement for five years with a monthly payment of $7,400 in order to apply for a license and build-out of a location for a client. Also, on July 22, 2014 one of the Company’s subsidiaries Medbox Property Investments, Inc., entered into a new lease for a facility which will be used in the application process for both a dispensary and cultivation facility. The Company paid an initial security deposit of $30,000 and the lease is payable monthly at a rate of $20,000 per month. The lease has a five year term, but is contingent upon license approval which allows for early termination of the lease after January 1, 2015 if the license is not granted. Due to the fact that the Company was unsuccessful in obtaining the license related to the mentioned facility the lease agreement was terminated in November 2014.
	The following table is a summary of our material contractual lease commitments as of December 31, 2014:
	Year Ending	Office Rent		Retail/Cultivation
				Facility Lease
	2015	$	177,936	$	88,800
	2016		177,936		88,800
	2017		88,968		88,800
	2018		—		88,800
	2019		—		29,600
	Total	$	444,840	$	384,800
	Real Estate Commitments
	As part of the changes in the Company’s business model, the Company entered in various real estate purchase agreements at various times in order to allow the filing of retail dispensary or cultivation facility licenses in certain states and localities. These purchase agreements generally provide for a period of due diligence and a termination clause in the event that the Company is unable to obtain a license for its client. The agreements generally also provide for some monthly payment from escrow in order to compensate the real estate owner for the passage of time until the sale transaction is complete. Most of these payment releases from escrow are nonrefundable but applicable towards the purchase price if the Company decides to proceed with the purchase. Subject to approval of the license for a dispensary or cultivation center, the Company intends to close on the real estate where purchase agreements have been signed, or to seek partners to replace the Company on each property purchased.
	During the year ended December 31, 2014, the Company paid $930,000, either by deposit into fifteen escrow accounts or direct payments to sellers, to secure the purchase and/or extend the closing dates on real estate to be used for future retail/cultivation facilities with an aggregate purchase price of $26,830,000. During the same period, the Company allowed the escrows to expire on three agreements with an aggregate purchase price of $3,195,000 and forfeited $140,000 in earnest money due to unfavorable terms demanded by the sellers to extend the escrow and closing date.
	The Company was not successful in obtaining licenses for another ten locations with an aggregated sales price of $21,515,000 and deposits in escrow totaling $685,000. As a result all escrow accounts were closed with $235,757 forfeited and $419,167 refunded to the Company in 2014, with an additional $30,076 of escrow deposits to be refunded in January 2015.
	The remaining two real estate purchase agreements have closing dates of March 31, 2015.
	During July, 2014, one of the real estate properties on which the Company opened escrow was foreclosed upon and the agreement was canceled and the escrow in the amount of $10,000 was reimbursed to the Company on July 28, 2014.
	During the second quarter of 2014 one of the Company’s subsidiaries entered into a real estate purchase agreement in Washington state. The purchase transaction was closed during the third quarter for a total purchase price of $399,594 partially financed by a promissory note for $249,000.
	A summary of open real estate purchase transactions as of December 31, 2014 is represented in the table below:
	Property	Purchase price		Closing		Net escrow		Date		Additional
				date		balance		escrow		rents/fees paid
								opened		to extend closing
										date
	1	$	820,000		3/31/15		55,000		6/28/14	$	9,808
	2		1,300,000		3/30/15		50,000		10/17/14
	3		—				265,400		7/21/14		—
	Escrow deposits to be refunded						30,076
	Total	$	2,120,000			$	400,476			$	9,808
	Line 3 represents the advance on July 21, 2014 of $75,000 to PVMI, a related party, as a partial payment for advances made by PVMI for escrow deposits used to secure properties for possible license acquisition in the San Diego market area and $190,400 from the assignment agreement.
	On October 17, 2014, the Company entered into an assignment agreement with PVMI through which PVMI assigned all rights and titles for any opened escrow on real estate purchase agreements in San Diego in exchange for a related party notes payable from the Company. As of the signing date the agreement was valued at $190,400 which represented the value of escrow deposits paid by PVMI for eight different real estate agreements. Also on the date of the assignment agreement the Company paid $50,000 into an escrow account (line item 2 from the table above) for PVMI. The escrow was related to one of the eight real estate purchase agreements that were part of the assignment.
	Board of Directors and Officers
	On October 13, 2014, Mr. Vincent Mehdizadeh resigned as an officer of the Company. Mr. Mehdizadeh continued to serve as a consultant to the Company. In his new role, Mr. Mehdizadeh provided consulting services under the title of Founder and Senior Advisor. In connection therewith, on October 13, 2014, the Company entered into a consulting agreement with Mr. Mehdizadeh, pursuant to which the Company agreed to pay Mr. Mehdizadeh a monthly fee of $25,000 for consulting services to be performed by Mr. Mehdizadeh. The monthly consulting fee was reduced to $12,500 per month if Mr. Mehdizadeh is engaged in trading any of the Company’s securities at any time within the preceding 30 day period. The consulting agreement had a two-year term., and a total of $12,375 was paid to Mr. Mehdizadeh under this agreement. Mr. Mehdizadeh’s consulting agreement was terminated on December 8, 2014.
	On October 16, 2014, Thomas Iwanski resigned as Chief Financial Officer, and C. Douglas (“Doug”) Mitchell was elected as Chief Financial Officer of the Company and Corporate Secretary.
	Mr. Iwanski agreed to serve as a consultant to the Company for a transition period. The Company agreed to pay Mr. Iwanski $10,000 for services provided during the month of October 2014 and $200 per hour for consulting services rendered after October 31, 2014. The Company also agreed to issue Mr. Iwanski 100,000 Restricted Stock Units (“RSU’s”) for his service to the Company.
	In connection with Mr. Doug Mitchell’s election as Chief Financial Officer, on October 16, 2014, the Company entered into an employment agreement with Mr. Mitchell (the “Employment Agreement”). Pursuant to the Employment Agreement, the Company agreed to engage Mr. Mitchell, and Mr. Mitchell agreed to serve as the Company’s Chief Financial Officer, for a two-year term, which term will automatically be extended for successive additional one-year terms, unless either party provides written notice to the other 90 days prior to the expiration of the initial term or any successive term, that the Employment Agreement will not be renewed. The Company agreed to pay Mr. Mitchell a salary of $190,000 per year and to pay Mr. Mitchell $2,500 per month for living expenses in the West Hollywood, California area. Mr. Mitchell will also be entitled to an annual bonus of up to 35% of his salary, payable of up to 50% in cash and the balance payable in equity of the Company, subject to performance criteria and objectives to be established by mutual agreement of the CEO of the Company and Mr. Mitchell within 90 days of the effective date of the Employment Agreement, and thereafter from time to time by the CEO in consultation with Mr. Mitchell. Mr. Mitchell will also be entitled to an award of restricted stock units, to be issued within 90 days of the effective date of the Employment Agreement, under the Company’s Equity Incentive Plan, in the amount of 7,500 shares of common stock each calendar quarter Mr. Mitchell serves as Chief Financial Officer of the Company.
	The Company may terminate the Employment Agreement with or without Cause (as defined in the Employment Agreement) upon written notice to Mr. Mitchell. In the event the Company terminates the Employment Agreement without Cause, Mr. Mitchell terminates the Employment Agreement with Good Reason (as defined in the Employment Agreement), or the Employment Agreement is not renewed as a result of notice to Mr. Mitchell provided 90 days prior to expiration of the initial or a renewal term, Mr. Mitchell will be entitled to payment of one-half his annual salary. Termination by the Company within 365 days of a Change of Control (as defined in the Employment Agreement) in the absence of Cause will conclusively be deemed a termination by the Company without Cause.
	On October 22, 2014, Jennifer S. Love was elected to the board of directors of the Company. Ms. Love was also elected to serve as Chairperson of the Audit Committee. Jennifer Love was granted 19,452 RSU’s for 2014. Her contract calls for grants of 100,000 RSU’s for each succeeding year of service beginning on April 1, 2015.
	Contingencies – SEC investigation
	In October 2014 the Board of Directors of the Company appointed a special board committee (the “Special Committee”) to investigate a federal grand jury subpoena pertaining to the Company’s financial reporting which was served upon the Company’s then independent public accounting firm, as well as certain alleged wrongdoing raised by a former employee of the Company. Thereafter the Company was served with two subpoenas from the Securities and Exchange Commission in early November 2014. In connection with its investigation of these matters, the Special Committee in conjunction with the Audit Committee initiated an internal review by management and by an outside professional advisor of certain prior period financial reporting of the Company. As a result of this review, the Company determined there were errors in properly recording the revenue on certain customer contracts, capital contributions from related parties and improper capitalization of inventory costs. As a result, the Company restated the Company’s consolidated financial statements for the years ended December 31, 2012 and 2013 reported in the Company’s General Form of Registration of Securities on Form 10/A and the condensed consolidated financial statements as of and for the quarterly periods ended March 31, June 30, and September 30, 2014 and 2013.
	The SEC is trying to determine whether there have been any violations of the Federal Securities Laws. It said further that the fact of the investigation does not mean that it has concluded that the Company or anyone else has broken the law or that it has a negative opinion of any person, entity or security. The Company is cooperating with the SEC in the investigation.
	Registration Statement
	The registration rights agreement entered into in connection with the July and September 2014 purchase agreements required the Company to have a Form S-1 declared effective on or before November 18, 2014. Due to the restatement discussed above, the registration statement has been delayed. As a result of the withdraw of the Form S-1, in January 2015 the Company agreed with the lenders to adjust the conversion rate for the amortization payments and reduced the volume weighted average price for 20 days prior to the issuance to 51%. See Note 20 Subsequent Events for purchase agreement modifications finalized in January 2015.
	Litigation
	On May 22, 2013, Medbox initiated litigation in the United States District Court in the District of Arizona against three shareholders of MedVend Holdings LLC (“Medvend”) in connection with a contemplated transaction pursuant to which Medbox entered into for the purchase of an approximate 50% ownership stake in MedVend for $4,100,000. The Company paid an advance of $300,000 upon execution of the contract, and another $300,000 was disbursed as an additional investment to MedVend. The lawsuit alleges fraud and related claims arising out of the contemplated transaction during the quarter ended March 31, 2013. The litigation is pending and Medbox has sought cancellation of the agreement due to a fraudulent sale of the stock because the selling shareholders lacked power or authority to sell their ownership stake in MedVend, and their actions were a breach of representations made by them in the agreement. On November 19, 2013 the litigation was transferred to United States District Court for the Eastern District of Michigan. MedVend recently joined the suit pursuant to a consolidation order executed by a new judge assigned to the matter. In the litigation, the selling shareholder defendants seek alternatively to have the transaction performed, or to have it unwound and seek damages. Medbox has denied liability with respect to any and all such counterclaims. A new litigation schedule was recently issued setting trial for September 2015. On June 5, 2014, the Company entered into a purchase and sale agreement (the “Medvend PSA”) with PVM International, Inc. (“PVMI”) concerning this matter. Pursuant to the Medvend PSA, the Company assigned to PVMI the Company’s rights and claims attributable to or controlled by the Company against those three certain selling stockholders of Medvend, known as Kaplan, Tartaglia and Kovan, (the “Medvend Rights and Claims”) in exchange for the return by PVMI to the Company of 30,000 shares of the Company’s common stock. PVMI is owned by Vincent Mehdizadeh, the Company’s largest stockholder. The Company will have the right, under the Medvend PSA, to purchase from PVMI, at any time, the Medvend Rights and Claims, for the consideration provided by PVMI, plus the sum of any of PVMI’s reasonable expenditures incurred in pursuit of the Medvend Rights and Claims. The Court has not yet ruled on the substitution of PVMI as plaintiff in this matter. If necessary, the Company plans to vigorously defend against this matter. The case is in the discovery stage, and, at this time, the Company cannot determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can they reasonably estimate a range of potential loss, should the outcome be unfavorable.
	In January 2015, three separate class action suits were been filed against the Company, certain past and present members of management, and the Company’s Board of Directors. These suits allege that the Company violated federal securities laws by allegedly making materially false and misleading statements regarding the Company’s financial results. The Company has only been served with a complaint on one of these cases, Crystal v. Medbox, Inc., Mehdizadeh, Bedrick, Iwanski, Marasala, and Mitchell. On February 12, 2015, the Court issued an Order Extending Time to Respond to Complaint until such time “any related actions are consolidated, a lead plaintiff and lead counsel are appointed by the Court, the lead plaintiff serves an operative complaint,” and certain other events. The Company intends to vigorously defend itself against these suits. Due to the early stages of the suits, the Company is unable to determine whether the likelihood of an unfavorable outcome of these suits is probable or remote, nor can it reasonably estimate a range of potential loss, including coverage by the Company’s insurance carrier, should the outcome be unfavorable.
	On February 20, 2015, a derivative claim was filed, entitled Glitner v. Medbox, wherein the Company was named as both a nominal plaintiff and a defendant and all members of the Company’s Board of Directors were named as individual defendants. The lawsuit seeks damages for breach of fiduciary duties and abuse of control. The Company intends to vigorously defend itself against these suits. Due to the early stages of the suits, the Company is unable to determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can it reasonably estimate a range of potential loss, should the outcome be unfavorable.
	The Company has accrued an additional $500,000 in legal fees to represent amounts they are expecting to pay in excess of the defense costs paid by their insurance Company.
	The Company also is the plaintiff in a legal action with a customer to collect past due balances in the amount of approximately $550,000 from the customer. The customer filed a cross complaint for breach of contract and breach of implied covenant of good faith and fair dealing in which the customer claims damages of not less than $500,000. The Company does not believe the cross complaint is meritorious and intends to continue to pursue the amounts due from the customer, and to vigorously defend itself against the claim. At this time, the Company is unable to determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can it reasonably estimate a range of potential loss, should the outcome be unfavorable.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 20 – SUBSEQUENT EVENTS
	Litigation
	On or about January 9, 2015, PVM International, Inc., Vincent Chase, Inc., and Vincent Mehdizadeh, in his individual capacity, (collectively the “VM Parties”) jointly executed that certain “Action by Written Consent of the Stockholders of Medbox, Inc.” (the “Written Consent”) seeking to appoint four successor directors the Company’s board of directors (the “Board”) as of January 29, 2015.
	On January 16, 2015, the Company filed a complaint in Los Angeles Superior Court disputing the legal effectiveness of the Written Consent (the “Complaint”).
	On January 21, 2015, the Company, P. Vincent Mehdizadeh, PVM International, Inc., (“PVM”), and Vincent Chase, Incorporated, (“VC”) entered into an agreement pursuant to which (1) the VM Parties acknowledged that the Written Consent was cancelled and withdrawn, (2) the parties agreed to enter into a Voting Agreement to vote in favor of and to not remove directors Ned L. Siegel (“Siegel”), Mitch Lowe (“Lowe”), Jennifer Love (“Love”) and Guy Marsala (“Marsala”) for a period of 12 months (the “Voting Agreement”), (3) the Company would dismiss the Complaint with prejudice, (4) the Board would meet with Mr. Mehdizadeh on specified dates during the term of the agreement to discuss and to hear matters of interest or concern of Mr. Mehdizadeh, as a stockholder of the Company (the “Agreement”). Each of the directors of the Company are also parties to the Voting Agreement.
	Pursuant to the terms of the Agreement, the VM Parties may on or before January 25, 2015, present a term sheet to the Company from an accredited investor to invest in not less than $1,000,000 in restricted common stock of the Company on terms as reasonably agreed to by the Board (the “Private Placement”). In addition, either as part of the closing of the Private Placement or otherwise at the request of Mr. Mehdizadeh, Mr. Mehdizadeh shall have the right to appoint a person nominated by Mr. Mehdizadeh with industry experience and reasonably acceptable to the Board as the fifth director of the Company.
	Amendment and Modification of the July 2014 Financing
	On July 21, 2014, Medbox, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with accredited investors (the “Investors”) pursuant to which the Company agreed to sell, and the Investors agreed to purchase, convertible debentures (the “Debentures”) in the aggregate principal amount of $3,000,000, in three tranches, each in the amount of $1,000,000. The initial closing under the Purchase Agreement, for Debentures in the aggregate principal amount of $1,000,000 occurred on July 21, 2014. See the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on July 25, 2014. The Investors subscribed for an additional $1,000,000 on August 25, 2014, an additional $500,000 on September 24, 2014, and an additional $250,000 on November 24, 2014 (collectively, with the July 21 Debenture, the “Original Debentures”).
	On January 30, 2015, the Company and the Investors entered into an Amendment, Modification and Supplement to the Purchase Agreement (the “Purchase Agreement Amendment”) pursuant to which the Investors will purchase an additional $1,800,000 in seven Modified Closings: (1) $200,000 was funded at the Closing of the Purchase Agreement Amendment; (2) $100,000 will be funded within thirty (30) days of the Closing; (3) $100,000 will be funded within two days following the filing of a registration statement with the SEC to register the shares underlying the Debentures (the “Registration Statement”) and of the Company having filed with the SEC a restatement of the Company’s consolidated financial statements as described in the Company’s Current Report on Form 8-K filed with the SEC on December 22, 2014; (4) $100,000 will be funded within two days of receipt of the first comment letter from the SEC with regard to the Registration Statement; (5) $500,000 will be funded within two days of the date that the Registration Statement is declared effective by the SEC; (6) $500,000 will be funded within five days of the date that the Registration Statement is declared effective by the SEC; and (7) $100,000 will be funded within each of 90, 120, 150, and 180 days from the Closing of the Purchase Agreement Amendment. The Parties entered into a Modified Debenture Agreement for the $200,000 that was funded at the Closing and agreed to use the same form of Modified Debenture for each of the other foregoing Modified Closings (collectively, the “Modified Debentures”). The parties also entered into a warrant instrument granting the Investor the right to purchase shares of common stock of the Company equal to the principal amount of the applicable Modified Debenture divided by a price (the “Reference Price”) equal to 120% of the last reported closing price of the Common stock on the applicable closing date of the Modified Debenture, at an exercise price equal to the Reference Price, with a three year term. The Company also entered into a Debenture Amendment Agreement and an Amended and Restated Debenture for the amount outstanding under the original Debenture, (1) reflecting the terms set forth above, (2) providing for accrued and unpaid interest to be payable upon conversion or maturity rather than on specified payment dates and (3) amending the conversion price of the Debenture to be equal to the lower of $5.00 or 51% of the lowest volume weighted average price for the 20 consecutive trading days prior to the applicable conversion date. In connection with the Purchase Agreement Amendment, the Company is also required to open a new dispensary in Portland, Oregon during the first calendar quarter of 2015, as a condition to closing the fourth, fifth and sixth Modified Closings set forth above. With respect to each of the Modified Closings, the Company will pay a fee to the Investors in the amount equal to 5% of the Subscription Amount of the applicable Modified Closing. The Company must also file the Registration Statement by April 30, 2015 (as amended), and it must be declared effective by June 15, 2015 in order to avoid default and acceleration under the Amended and Restated Debenture.
	On March 13, 2015 the Company and the Investors entered into a further amendment (“March 2015 Amendment”) to the July 21, 2014, 10% Convertible debentures, as amended January 30, 2015, whereby the fixed conversion rate was lowered to $1.83, and the anti-dilution reset provision on all previous debentures was triggered. In addition, the March 2015 Amendment modified the filling date requirement for the Registration Statement to be April 30, 2015.
	Amendment and Modification of September 2014 Financing
	On September 19, 2014, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with an accredited investor (the “Investor”) pursuant to which the Company agreed to sell, and the Investor agreed to purchase, convertible debentures (the “Debentures”) in the aggregate principal amount of $2,500,000, in two tranches, the first in the amount of $1,000,000, and the second in the amount of $1,500,000. The initial closing under the Purchase Agreement, for a Debenture in the principal amount of $1,000,000, occurred on September 19, 2014. See the Company’s Current Report on Form 8-K filed with the SEC on September 24, 2014.
	On January 28, 2015, the Company and the Investors entered into an Amendment, Modification and Supplement to the September 19, 2014 Purchase Agreement (Note (the “Purchase Agreement Amendment”) pursuant to which the remaining $1,500,000 will be funded in four Modified Closings: (1) $100,000 was funded at the Closing of the Purchase Agreement Amendment; (2) $100,000 will be funded within two days following the filing of a registration statement with the SEC to register the shares underlying the Debentures (the “Registration Statement”) and of the Company having filed with the SEC a restatement of the Company’s consolidated financial statements as described in the Company’s Current Report on Form 8-K filed with the SEC on December 22, 2014; (3) $100,000 will be funded within two days of receipt of the first comment letter from the SEC with regard to the Registration Statement; and (4) $1,200,000 will be funded within two days of the date that the Registration Statement is declared effective by the SEC. The Parties entered into a Modified Debenture Agreement for the $100,000 that was funded at the Closing and agreed to use the same form of Modified Debenture for each of the other foregoing Modified Closings (collectively, the “Modified Debentures”). The parties also entered into a warrant instrument granting the Investor the right to purchase shares of common stock of the Company equal to the principal amount of the applicable Modified Debenture divided by a price (the “Reference Price”) equal to 120% of the last reported closing price of the Common stock on the applicable closing date of the Modified Debenture, at an exercise price equal to the Reference Price, with a three year term. The Company also entered into a Debenture Amendment Agreement and an Amended and Restated Debenture for the amount outstanding under the original Debenture, (1) reflecting the terms set forth above, (2) providing for accrued and unpaid interest to be payable upon conversion or maturity rather than on specified payment dates and (3) amending the conversion price of the Debenture to be equal to the lower of $5.00 or 51% of the lowest volume weighted average price for the 20 consecutive trading days prior to the applicable conversion date. In connection with the Purchase Agreement Amendment, the Company is also required to open a new dispensary in Portland, Oregon during the first calendar quarter of 2015, as a condition to closing the second, third and fourth Modified Closings set forth above. With respect to each of the Modified Closings, the Company will pay a fee to the Investors in the amount equal to 5% of the Subscription Amount of the applicable Modified Closing. The Company must also file the Registration Statement by April 30, 2015 (as amended), and it must be declared effective by June 15, 2015 in order to avoid default and acceleration under the Amended and Restated Debenture.
	In connection with the Closing of the Purchase Agreement Amendments for the July 2014 Financing and the September 2014 Financing, Mr. Ned L. Siegel, the chairman of the Company’s Board, entered into two separate subordinated convertible promissory notes with the Company on January 5, 2015 and January 30, 2015, respectively, each in the principal amount of $50,000 and having a three year term and an interest rate of 8% per annum (the “Siegel Notes”). In addition, Mr. Mitchell Lowe, a member of the Board, entered into one subordinated convertible promissory note with the Company on February 2, 2015 in the principal amount of $50,000 and having a three year term and an interest rate of 8% per annum (the “Lowe Note”).
	Mr. Siegel and Mr. Lowe are entitled to receive a warrant, exercisable for a period of five (5) years from the date of grant, to purchase an amount of Company Common Stock equal to 50% of the principal sum under each of the Siegel Notes and the Lowe Note, respectively, at an exercise price equal to 200% of the applicable Conversion Price (the “Warrants”). The Conversion Price of the Warrants is either (i) 85% of the volume-weighted average price of the Common Stock for the thirty trading days prior to notice of Conversion or (ii) 85% of the per share price of the Company’s next common stock offering of not less than $2 million. Mr. Siegel and Mr. Lowe also received registration rights for the shares underlying the Siegel Notes and the Lowe Notes, respectively.
	Notes payable
	During February 2015 the Company entered into a modified loan agreement with the holder of a $249,000 note payable when they were unable to repay the note on its maturity date. Under the revised loan agreement, the Company agreed with the lender to an extension of the maturity date to July 1, 2015, and increased the interest rate to 18% plus a late charge in the amount of 5% of the principal balance of the note.
	Shares issued
	On January 15, 2015 the Company issued 206,480 shares to satisfy the conversion of remaining warrants related to the settlement with various previous owners of Vapor Systems International, LLC.
	Share purchase and transfer
	On March 5, 2015 Mr. Mehdizadeh announced that an agreement has been executed with Lizada Capital LLC, an investor in the field of legal cannabis products, that would result in the transfer of the majority of Mr. Mehdizadeh’s shares of the Company to that firm. Under the agreement, Lizada would purchase 22,160,000 shares, representing 2,000,000 preferred shares and 12,160,000 common shares of Medbox for consideration of approximately $15 million. A total of $5 million of the funds have been designated for purchase of restricted shares of the Company’s common stock, directly from the Company, at $2 per share in the name of Mr. Mehdizadeh’s holding company, PVM International, Inc.
	The transaction has 6 separate closings over the course of 18 months, with each of the first five closings being in the amount of $2 million dollars to be paid to Mehdizadeh’s holding company and Medbox equally, or $1 million to each party, to satisfy the $5 million dollar direct investment component of the transaction. The 6th and final closing has a performance contingency and is in the amount of $5 million dollars paid directly to Mehdizadeh’s holding company.
	A representative of Lizada will join Medbox’s Board of Directors within the next 90 days, after the first closing is set to occur.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Principles of Consolidation

Principles of Consolidation

The consolidated financial statements include the accounts of Medbox, Inc. and its wholly owned subsidiaries, as named in Note 1 above. All intercompany transactions have been eliminated.

Use of Estimates

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the consolidated financial statements as well as the reported expenses during the reporting periods. The Company’s significant estimates and assumptions include the valuation of the Company’s common stock used in the valuation of goodwill, accounts receivable and note receivable collectability, inventory, advances on investments, the valuation of restricted stock and warrants received from customers, the amortization and recoverability of capitalized patent costs and useful lives of long-lived assets the derivative liability, and income tax expense. Some of these judgments can be subjective and complex, and, consequently, actual results may differ from these estimates. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Actual results could differ from these estimates.

Concentrations of Credit Risk

Concentrations of Credit Risk

The Company maintains cash balances at several financial institutions in the Portland, Oregon, Los Angeles, California area and Florida. Accounts at each institution are insured by the Federal Deposit Insurance Corporation up to $250,000. The Company has not experienced any losses in such accounts and periodically evaluates the credit worthiness of the financial institutions and has determined the credit exposure to be negligible.

Three customers, one of which is a related party through the entity’s stock ownership in the Company (customer C) represented 65.1% of the total revenue of $696,407 for the year ended December 31, 2014.

Customer

December 31, 2014

January -

December 31, 2013

January -

December 2014

December 2013

Accounts Receivable

Revenue

Accounts Receivable

Revenue

Amount, $

%

Amount, $

%

Amount, $

%

Amount, $

%

A

$

—

—

%

$

203,165

29.2

%

$

150,000

44.2

%

$

325,000

15.8

%

B

—

—

175,000

25.1

115,200

33.9

—

—

C

—

—

75,301

10.8

—

—

—

—

Subtotal

—

0

453,466

65.1

265,200

78.1

$

325,000

15.8

%

Total

$

8,774

100

%

$

629,132

100

%

$

339,735

100

%

$

2,062,083

100

%

Advertising and Marketing Costs

Advertising and Marketing Costs

Advertising and marketing costs are expensed as incurred. The Company incurred advertising and marketing costs of $933,627, $644,383 and $806,221  for the years ended December 31, 2014, 2013 and 2012, respectively.

Research and Development

Research and Development

Research and development expenses are charged to operations as incurred. The Company incurred research and development costs of $242,232, $74,861 and $176,964 for the years ended December 31, 2014 2013 and 2012, respectively.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Pursuant to ASC No. 825, Financial Instruments, the Company is required to estimate the fair value of all financial instruments included on its balance sheets. The carrying value of cash, accounts receivable, other receivables, inventory, accounts payable and accrued expenses and notes payable, related party notes payable, customer deposits, provision for customer refunds and short term loans payable approximate their fair value due to the short period to maturity of these instruments. The Company’s marketable securities and related customer deposits require fair value measurement on a recurring basis as the Company has received advance payment of restricted stock in a publicly traded company for contracted services and received warrants for service provided to unrelated third party. The Company has no exposure to gain or loss on the increase or decrease in the value of the marketable securities received as a payment from customer as any shortfall in the ultimate liquidated value of the securities will be supplemented by additional restricted stock from the customer and any liquidation in excess above the Company’s billings will be returned to the customer. The securities received as a payment for services provided will be exposed to gains or losses following their initial evaluation as of the date the revenue was earned.

Warrants and other financial assets received as a payment for the services provided are recorded as “Marketable securities” under the current assets if they are expected to be realized within 12 months. The Company uses the Black-Scholes model to measure the value of the warrants. At each reporting date the Company will reevaluate the value of marketable securities and record any changes in value to other comprehensive income (loss) under “Unrealized gain or losses from marketable securities”.

Unrealized gain or loss from marketable securities occurs in the process of the reevaluation of the warrants or other financial assets after their initial recognition valuation. At each reporting date the Company reevaluates the value of marketable securities and reflects the change in the statement of changes in equity under other comprehensive income (loss).

Embedded derivative – The Company’s convertible notes payable include embedded features that require bifurcation due to a reset provision and are accounted for as a separate embedded derivative (see Note 13). The Company has estimated the fair market value of the embedded derivative of the Notes based on a weighted probability model. The key valuation assumptions used consist of the price of the Company’s stock, a risk free interest rate based on the average yield of a one year Treasury note and expected volatility of the Company’s common stock all as of the measurement dates, and various estimated reset exercise prices allocated by probability. The Company considers these inputs Level 3 assumptions, based on the application of the estimated probability rate being considered an unobservable input.

A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:

Level 1

Quoted prices in active markets for identical assets or liabilities.

Level 2

Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly.

Level 3

Significant unobservable inputs that cannot be corroborated by market data.

The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of the relevant assets and liabilities that are measured at fair value on a recurring basis.

Total

Quoted Prices

Quoted Prices

Significant

in Active

for Similar

Unobservable

Markets for

Assets or

Inputs

Identical

Liabilities in

(Level 3)

Assets or

Active

Liabilities

Markets

(Level 1)

(Level 2)

December 31, 2014

Marketable securities

$

94,776

$

$

$

94,776

Derivative liability

3,691,853

—

—

3,691,853

Total

$

3,786,629

$

$

—

$

3,786,629

Total

Quoted Prices

Quoted Prices

Significant

in Active

for Similar

Unobservable

Markets for

Assets or

Inputs

Identical

Liabilities in

(Level 3)

Assets or

Active

Liabilities

Markets

(Level 1)

(Level 2)

December 31, 2013

Marketable securities

$

184,800

$

184,800

$

—

$

—

Total

$

184,800

$

184,800

$

—

$

—

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis:

For the year ended

December 31, 2014

Total

Beginning balance

$

—

Initial recognition of conversion feature

1,885,863

Change in fair value of conversion feature

1,805,990

Ending balance

$

3,691,853

Revenue Recognition

Revenue Recognition

Our current revenue model consists of the following income streams:

Consulting fee revenues.

Consulting fee revenues. This revenue stream is a consistent component of our current and anticipated future revenues and is negotiated at the time we enter into a contract. In jurisdictions where there is intense competition for a limited number of dispensing or cultivating licenses, we believe the Medbox model, with its incorporated security measures, promotes a distinct advantage in the application selection process for such licenses, especially in the states where an applicant is graded on the ability to demonstrate compliance with applicable law.

Consulting fee revenue is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonable assured. For multi-year contracts with upfront payments made by customers, the upfront payments are recognized over the longer of the contract period or the customer relationship. For contracts that include multiple deliverables such as the build out of customer facilities, the Company recognizes revenue when a milestone is reached in the contract such as securing the location, delivery of dispensing machines or completion of the facility.

Revenues on dispensary unit and vaporizer sales. Medbox machines retail for approximately $50,000 for each machine set (including the POS system). In addition, many consulting contracts bundle the sale of the dispensary units within the scope of deliverables to be provided that might also include location build out costs. Bundling through consulting packages is the most common way that we sell and distribute Medboxes. Gross margins on our tabletop vaporizer sales and accessories are expected to initially average out to a net loss position due to initial higher manufacturing costs prior to implementation of the cost reduction process that we have undertaken. The introduction of our portable miVape product in the second quarter of 2015 is expected to provide a cost effective product with industry standard margins while providing significant value to the customer.

Revenue on dispensary unit sales is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonable assured. For contracts that include multiple deliverables such as the build out of customer facilities, the Company recognizes revenue when a milestone is reached in the contract such as securing the location, delivery of dispensing machines or completion of the facility. The contract terms are broken down in specific milestones with specific attributable revenue to be earned upon successful completion of the milestone terms. (i.e. if a milestone is completing construction on a client dispensary, the condition for the revenue to be recorded is after issuance of a certificate of occupancy for the newly completed facility. The Company will record a specified amount of revenue attributable to this milestone based on the contract). Equipment sales not associated with a consulting contract are recognized as the product is shipped and title passes. Vaporizer sales are recognized as the product is shipped.

Other revenue includes sales of territory rights, sales/leases of management rights of newly awarded dispensary licenses, and sales/leases of management rights of newly acquired dispensary licenses and physical locations. We enter into transactions with clients who are interested in being granted the right to have us engage exclusively with them in certain territories (which we describe as territory rights), operating existing dispensary locations and buying previously issued dispensary licenses. Terms for each deal are varied and the sales arrangements typically include the delivery of our dispensing technology and dispensary location build-out. We will also seek to enter into contracts to assign exclusive management rights we have been granted by licensees under management rights agreements for retail, dispensary, or cultivation centers for which we have facilitated the granting of licenses.

Other revenue is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonable assured. For multi-year contracts with upfront payments made by customers, the upfront payments are recognized over the longer of the contract period or the customer relationship. For contracts that include multiple deliverables such as the build out of customer facilities, the Company recognizes revenue when a milestone is reached in the contract such as securing the location, delivery of dispensing machines or completion of the facility. The contract terms are broken down in specific milestones with specific attributable revenue to be earned upon successful completion of the milestone terms. (i.e. if a milestone is completing construction on a client dispensary, the condition for the revenue to be recorded is after issuance of a certificate of occupancy for the newly completed facility. The Company will record a specified amount of revenue attributable to this milestone based on the contract. Advance payments from clients in advance of work performed are recorded as customer deposits on the balance sheet.

Revenue from referral fees and revenue sharing from real estate transactions with partners. The Company expects to generate revenue from matching its clients with a real estate financing partner to facilitate property purchases and subsequent leasebacks to our clients at a premium to market rates due to the sensitive use (in particular, marijuana retail (sale for recreational purposes)), dispensary (sale for medical purposes) and cultivation (marijuana growth and production of marijuana edibles)

Referral fee and revenue sharing revenue is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonable assured. For multi-year contracts with upfront payments made by customers, the upfront payments are recognized over the longer of the contract period or the customer relationship. If all required deliverables are complete, the referral fee will be recognized when the customer closes on the subject transaction.

Revenue from providing monthly compliance and accountability support to dispensary operators. The Company expects to generate revenue from providing monthly compliance and accountability support to dispensary operators. Such services will entail bi-weekly onsite reviews of client dispensaries to ensure regulatory compliance, transaction and taxation reporting transparency, and adherence to state licensing guidelines for licensing renewal purposes. Fees will vary in each market area. The Company expects to provide such services based upon internal standards we have established which we believe, if properly followed, will greatly aid the location licensee in its compliance with state and local laws concerning operations of the location.

Monthly compliance and accountability support revenue is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonable assured. Revenue is recognized monthly as the services are delivered to clients.

Cost of Revenue

Cost of Revenue

Cost of revenue consists primarily of expenses associated with the delivery and distribution of our products and services. These include expenses related to the manufacture of our dispensary units, construction expense related to the customer dispensary, site selection and establishment of licensing requirements, and consulting expense for the continued management of the dispensary unit build out, server and security equipment, rent expense, energy and bandwidth costs, and support and maintenance costs prior to when the client moves in. We only begin capitalizing costs when we have obtained a license and a site for operation of a customer dispensary or cultivation center. The previously capitalized costs are charged to cost of revenue in the same period that the associated revenue is earned. In the case where it is determined that previously inventoried costs are in excess of the projected net realizable value of the sale of the licenses then the excess cost above net realizable value is written off to cost of revenues. In addition, cost of revenue related to our vaporizer line of products consists of direct procurement cost of the products along with costs associated with order fulfilment, shipping, inventory storage and inventory management costs.

Inventory

Inventory

Inventory is stated at the lower of cost or market value. Cost is determined on a cost basis that approximates the first-in, first-out (FIFO) method.

Work in process and related capitalized costs includes costs to build out a dispensary in Portland Oregon that is expected to open in the second quarter of 2015. Costs include tenant improvements to the facility, furniture, fixtures and Medbox dispensary units to be used by the licensed operator. It is anticipated this dispensary will be operated by a Medbox licensed operator and revenue and related cost of revenue will be recorded in the statement of operations in the second quarter of 2015.

Basic and Diluted Net Loss Per Share

Basic and Diluted Net Loss Per Share

Basic net income/loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net income per share include the effects of any outstanding options, warrants and other potentially dilutive securities. The Company did not consider any potential common shares in the computation of diluted loss per share for the periods ending December 31, 2014, 2013 and 2012, due to the net loss, as they would have an anti-dilutive effect on EPS.

As of December 31, 2014 and 2013, the Company has 3,000,000 shares of Series A preferred stock outstanding with par value of $0.001 that could be converted into 15,000,000 shares of the Company’s common stock. As of December 31, 2012 there were 6,000,000 shares of Series A preferred stock outstanding, which could be converted into 30,000,000 shares. Additionally the Company has 206,480 warrants to purchase common stock outstanding as of December 31, 2014. The Company also has $3,750,000 in convertible debentures outstanding at December 31, 2014, whose underlying shares were not included as they are convertible at the holders’ option at an initial fixed conversion price of $11.75.

Accounts Receivable and Allowance for Bad Debts

Accounts Receivable and Allowance for Bad Debts

The Company is subject to credit risk as it extends credit to our customers for work performed as specified in individual contracts. The Company extends credit to its customers, mostly on an unsecured basis after performing certain credit analysis. Our typical terms require the customer to pay a portion of the contract price up front and the rest upon certain agreed milestones. The Company’s management periodically reviews the creditworthiness of its customers and provides for probable uncollectible amounts through a charge to operations and a credit to an allowance for doubtful accounts based on our assessment of the current status of individual accounts. Accounts still outstanding after the Company has used reasonable collection efforts are written off through a charge to the allowance for doubtful accounts. As of December 31, 2014 and December 31, 2013, the Company’s management considered all accounts outstanding fully collectible.

Property and Equipment

Property and Equipment

Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses accelerated depreciation methods for tax purposes where appropriate. The estimated useful lives for significant property and equipment categories are as follows:

Vehicles

5 years

Furniture and Fixtures

5 years

Office equipment

3 years

Assets Held for Resale

Assets Held for Resale

During 2014, the Company has entered into various real estate purchase agreements to support the filing of retail dispensary or cultivation facility licenses in certain states and localities. The cost of the acquired real estate is included in Assets Held for Resale on the consolidated balance sheet. The Company intends to sell the real estate to a long term investor after the license is granted. The Company does not depreciate assets held for resale.

Income Taxes

Income Taxes

The Company accounts for income taxes under the asset and liability method in accordance with ASC 740. The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred tax assets and liabilities are classified as current and non-current based on their characteristics. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.

In addition, the Company’s management performs an evaluation of all uncertain income tax positions taken or expected to be taken in the course of preparing the Company’s income tax returns to determine whether the income tax positions meet a “more likely than not” standard of being sustained under examination by the applicable taxing authorizes. This evaluation is required to be performed for all open tax years, as defined by the various statutes of limitations, for federal and state purposes.

Commitments and Contingencies

Commitments and Contingencies

Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and its legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed.

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed.

The Company accrues all legal costs expected to be incurred per event, up to the amount of their deductible.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. Generally Accepted Accounting Principles when it becomes effective. The new standard is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period and is to be applied retrospectively, with early application not permitted. The new standard permits the use of either the retrospective or cumulative effect transition method. We are currently evaluating the effect that ASU 2014-09 will have on our consolidated financial statements and related disclosures. We have not yet selected a transition method nor have we determined the effect of the standard on our ongoing financial reporting.

Management's Evaluation of Subsequent Events

Management’s Evaluation of Subsequent Events

The Company evaluates events that have occurred after the balance sheet date of December 31, 2014, through the date which the consolidated financial statements were issued. Based upon the review, other than described in Note 20 – Subsequent Events, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements.

Going Concern

Going Concern

The Company recently revised its business model and completed a restatement of its financial statements. The revision to the business model which plans for long term contracts to manage dispensaries or cultivation centers tends to defer revenue and cash flow while expensing the costs to develop markets currently. The recently completed restatements and the on-going investigations by the SEC and the Department of Justice have added general and administrative expenses. The Company also operates in a new, emerging industry where business models are still developing and finalizing new deals can take longer than in more mature industries.

The financial statements were prepared on a going concern basis. The going concern basis assumes that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. During the year ended December 31, 2014, the Company had a net loss of approximately $16.5 million, negative cash flow from operations of $6.3 million and negative working capital of $10.0 million. The Company will need to raise capital in order to fund its operations. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement a business plan. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

As disclosed in our Form 8-K dated January 28, 2015, our lenders have committed to an additional $3.3 million in funding as our annual SEC filings are completed and the Form S-1 filed with the SEC. Due diligence is in process between an investor and our majority shareholder to sell his majority position which would also yield $5 million in new equity capital for the Company over the next 18 months (see Note 20). Management is committed to conducting a road show after the Form S-1 is declared effective to raise additional equity capital in 2015. The Company expects that these plans will provide it the necessary liquidity through the first quarter of 2016.

To address its financing requirements, the Company will seek financing through debt and equity financings. It is uncertain the Company can obtain financing to fund operating deficits until profitability is achieved. This need may be adversely impacted by: uncertain market conditions, approval of sites and licenses by regulatory bodies and adverse operating results. The outcome of these matters cannot be predicted at this time.

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Schedules of Concentration of Risk, by Risk Factor	Three customers, one of which is a related party through the entity’s stock ownership in the Company (customer C) represented 65.1% of the total revenue of $696,407 for the year ended December 31, 2014.
	Customer	December 31, 2014					January -					December 31, 2013					January -
							December 2014										December 2013
		Accounts Receivable					Revenue					Accounts Receivable					Revenue
		Amount, $		%			Amount, $		%			Amount, $		%			Amount, $		%
	A	$	—		—	%	$	203,165		29.2	%	$	150,000		44.2	%	$	325,000		15.8	%
	B		—		—			175,000		25.1			115,200		33.9			—		—
	C		—		—			75,301		10.8			—		—			—		—
	Subtotal		—		0			453,466		65.1			265,200		78.1		$	325,000		15.8	%
	Total	$	8,774		100	%	$	629,132		100	%	$	339,735		100	%	$	2,062,083		100	%
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of the relevant assets and liabilities that are measured at fair value on a recurring basis.
		Total		Quoted Prices			Quoted Prices		Significant
				in Active			for Similar		Unobservable
				Markets for			Assets or		Inputs
				Identical			Liabilities in		(Level 3)
				Assets or			Active
				Liabilities			Markets
				(Level 1)			(Level 2)
	December 31, 2014
	Marketable securities	$	94,776	$			$		$	94,776
	Derivative liability		3,691,853		—			—		3,691,853
	Total	$	3,786,629	$			$	—	$	3,786,629
		Total		Quoted Prices			Quoted Prices		Significant
				in Active			for Similar		Unobservable
				Markets for			Assets or		Inputs
				Identical			Liabilities in		(Level 3)
				Assets or			Active
				Liabilities			Markets
				(Level 1)			(Level 2)
	December 31, 2013
	Marketable securities	$	184,800	$	184,800		$	—	$	—
	Total	$	184,800	$	184,800		$	—	$	—
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis:
		For the year ended
		December 31, 2014
		Total
	Beginning balance	$	—
	Initial recognition of conversion feature		1,885,863
	Change in fair value of conversion feature		1,805,990
	Ending balance	$	3,691,853

PROPERTY_AND_EQUIPMENT_Tables

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2014
Property And Equipment [Member]
Property, Plant and Equipment	Property and equipment at December 31, 2014 and 2013 consists of:
	Property and Equipment	December 31, 2014			December 31, 2013
	Office equipment	$	22,421		$	17,192
	Furniture and fixtures		74,404			73,567
	Website development		46,922			46,922
	Product tooling		64,763			24,100
			208,510			161,781
	Less accumulated depreciation		(50,192	)		(21,123	)
	Property and equipment, net	$	158,318		$	140,658
Estimated Useful Lives [Member]
Property, Plant and Equipment	The estimated useful lives for significant property and equipment categories are as follows:
	Vehicles		5 years
	Furniture and Fixtures		5 years
	Office equipment		3 years

ACQUISITION_Tables

ACQUISITION (Tables)	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The total value of the acquisition was approximately $1,635,000 and the purchase price has been allocated as per the Company’s independent valuation as follows:
	Machinery and equipment	$	70,000
	IP and related technology		287,000
	Amortizable intangible assets:
	Customer contracts and related relationships		314,000
	Trade name, trademark, and domain name		46,000
	Non-compete covenants		23,000
	Goodwill		895,000
	Total assets acquired		1,635,000
	Fair value of liabilities assumed		(469,000	)
	Net fair value	$	1,166,000

INVENTORY_Tables

INVENTORY (Tables)	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	Inventory at December 31, 2014 and 2013 consists of the following:
		December 31, 2014		December 31, 2013
	Work in process and related capitalized costs	$	308,867	$	242,488
	Deposits on dispensing machines		325,973		138,423
	Vaporizers and accessories		154,930		193,575
	Dispensing machines		171,466		58,500
	Total inventory, net	$	961,236	$	632,986

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2014
Finite-Lived Intangible Assets [Member]
Schedule of Finite-Lived Intangible Assets
	Intangible assets	December 31, 2014			December 31, 2013
	Distributor relationship	$	314,000		$	314,000
	IP/technology/patents		324,653			332,179
	Domain names		131,000			46,000
	Non-compete covenants		23,000			23,000
	Subtotal		792,653			715,179
	Less accumulated amortization		(83,500	)		(32,750	)
	Intangible assets, net	$	709,153		$	682,429
Estimated Useful Lives [Member]
Schedule of Finite-Lived Intangible Assets	The estimated useful lives for significant intangible assets are as follows:
	Distributor Relationship		10 years
	Domain Names		10 years
	IP/Technology/Patents		10 years
	Non-Compete covenants		3 years

MARKETABLE_SECURITIES_Tables

MARKETABLE SECURITIES (Tables)	12 Months Ended
	Dec. 31, 2014
Marketable Securities	Marketable securities of the Company represent the shares received as a payment from clients for services provided.
	Marketable securities	Value as of		Value as of
		December 31, 2014		December 31, 2013
	Shares received as a payment from client	$	—	$	184,800
	Securities from MJ Holdings, Inc.		94,776		—
	Total marketable securities	$	94,776	$	184,800
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	The Company uses a Black-Scholes model to measure the value of the warrants. The following assumptions were used by the Company for the Black-Scholes model valuation of the warrants as of their initial valuation:
	Black-Scholes Calculator Data	Initial Valuation and Recognition
		#1		#2			#3			#4		#5		#6
	Warrant
	Stock price, $		8.69		4			8			6.15		2.01		2.02
	Exercise price, $		6.42		8.45			7.87			6.95		3.53		2.56
	Time to maturity, Years		0.5		0.5			0.5			0.5		1		1
	Annual risk-free rate, %		0.05		0.05			0.05			0.05		0.04		0.11
	Annualized volatility, %		70		70			70			70		70		70
	Black-Scholes Value per warrant, $		2.876		0.08			1.616			0.918		0.214		0.391
	Number of warrants/shares		33,333		33,333			33,333			33,333		33,333		33,333
	Total value of warrants/shares, $		95,866		2,666			53,867			30,600		7,133		13,033
	The following data were used by the Company for the Black-Scholes model valuation of the warrants as of December 31, 2014:
	Fair Value of Warrants	As of December 31, 2014
		#2		#3			#4			#5		#6
	Warrant
	Stock price, $		2		2			2			2		2
	Exercise price, $		8.45		7.87			6.95			3.53		2.56
	Time to maturity, Years		1		1			1			1		1
	Annual risk-free rate, %		0.22		0.22			0.22			0.22		0.22
	Annualized volatility, %		120		120			120			120		120
	Black-Scholes Value per warrant, $		0.25		0.27			0.31			0.6		0.77
	Number of warrants/shares		33,333		33,333			33,333			33,333		33,333
	Total value of warrants/shares, $		8,179		8,920			10,318			20,053		25,656
Warrant [Member]
Marketable Securities	The following table represents the initial recognition value and subsequent adjustment as of reporting date:
	Warrants	Initial Fair		Fair Value at			Gain or (Loss)			Fair Value as of
		Value		Conversion						December 31,
										2014
	Warrant #1	$	95,866	$	(94,719	)	$	(1,147	)	$	—
	Warrant #2		2,666					5,513			8,179
	Warrant #3		53,867					(44,947	)		8,920
	Warrant #4		30,600					(20,282	)		10,318
	Warrant #5		7,133					12,920			20,053
	Warrant #6		13,033					12,623			25,656
	Total	$	203,165	$	(94,719	)	$	(35,320	)	$	73,126

CUSTOMER_DEPOSITS_Tables

CUSTOMER DEPOSITS (Tables)	12 Months Ended
	Dec. 31, 2014
Banking and Thrift [Abstract]
Customer Advances And Deposits, Current	Advance payments from customers are recorded as customer deposits on the consolidated balance sheet.
	Customer deposits	December 31, 2014		December 31, 2013
	Advance payments from customers	$	1,450,770	$	710,225
	Advance payments for vaporizers		75,038		75,636
	Total customer deposits	$	1,525,808	$	785,861

PREPAID_EXPENSES_AND_OTHER_CUR1

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)	12 Months Ended
	Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure	Prepaid expenses and other currents assets consisted of:
		December 31,		December 31,
		2014		2013
	Rent	$	—	$	3,962
	Directors & officers insurance		31,491		—
	Professional fees		10,000		52,739
	Other vendors		24,729		32,540
	Prepaid expenses and other current assets	$	66,220	$	89,241

RESTRICTED_STOCK_AND_RESTRICTE1

RESTRICTED STOCK AND RESTRICTED STOCK UNITS ("RSUs") (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	A summary of the activity related to restricted stock and RSUs for the year ended December 31, 2014 is presented below:
	Restricted stock	Total shares			Grant date fair
					value
	Restricted stock non-vested at January 1, 2014		—		$	—
	Restricted stock granted		346,875			10.4
	Restricted stock vested		(178,125	)		10.4
	Restricted stock forfeited		—			—
	Restricted stock non-vested at December 31, 2014		168,750		$	10.4
	Restricted stock units (RSU’s)	Total shares			Grant date fair
					value
	Restricted stock non-vested at January 1, 2014		—		$	—
	Restricted stock granted		422,980			10.84
	Restricted stock vested		(223,396	)		11.19
	Restricted stock forfeited		—			—
	Restricted stock non-vested at December 31, 2014		199,584		$	10.7
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	A summary of the expense related to restricted stock and RSUs for the year ended December 31, 2014 is presented below:
	Summary of the expense related to Restricted Stock and RSUs	Year ended
		December 31, 2014
	Restricted Stock	$	663,262
	RSU’s		3,752,537
		$	4,415,799

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Significant Components of Deferred Tax Assets and Liabilities	Significant components of the Company’s deferred tax assets and liabilities are as follows at December 31:
		2014			2013
	Deferred tax assets:
	Customer deposits	$	295,000		$	293,000
	Deferred revenue		35,000
	Share based compensation		1,760,000
	NOL carryforward		5,400,000			2,377,000
	Total deferred tax asset		7,490,000			2,670,000
	Deferred tax liabilities:
	Deferred revenue		—			285,000
	Intangible asset amortization		20,000
			20,000			285,000
			7,470,000			2,385,000
	Less: Valuation allowance		(7,470,000	)		(2,385,000	)
		$	—		$	—
Reconciliation of Statutory Rate and Effective Rate for Provisions for Income Taxes	For the years ended December 31, 2014, 2013 and 2012, a reconciliation of the statutory rate and effective rate for the provisions for income taxes consists of the following:
		2014			2013			2012
	Federal Tax statutory rate		34	%		34	%		34	%
	State tax statutory rate		6	%		8.84	%		8.84	%
	Permanent differences		(6.72	)%		—	%
	Valuation allowance		(33.28	)%		(42.84	)%		(42.84	)%
	Effective rate		0	%		0	%		0	%

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Summary of Material Contractual Lease Commitments	The following table is a summary of our material contractual lease commitments as of December 31, 2014:
	Year Ending	Office Rent		Retail/Cultivation
				Facility Lease
	2015	$	177,936	$	88,800
	2016		177,936		88,800
	2017		88,968		88,800
	2018		—		88,800
	2019		—		29,600
	Total	$	444,840	$	384,800
Summary of Open Real Estate Purchase Transactions	A summary of open real estate purchase transactions as of December 31, 2014 is represented in the table below:
	Property	Purchase price		Closing		Net escrow		Date		Additional
				date		balance		escrow		rents/fees paid
								opened		to extend closing
										date
	1	$	820,000		3/31/15		55,000		6/28/14	$	9,808
	2		1,300,000		3/30/15		50,000		10/17/14
	3		—				265,400		7/21/14		—
	Escrow deposits to be refunded						30,076
	Total	$	2,120,000			$	400,476			$	9,808

NOTE_1_BUSINESS_ORGANIZATION_N

NOTE 1 - BUSINESS ORGANIZATION, NATURE OF OPERATIONS (Detail) (USD $)	12 Months Ended	0 Months Ended	12 Months Ended
	Dec. 31, 2012	Mar. 22, 2013	Dec. 31, 2014	Apr. 01, 2013
PVM International Inc. (PVMI) [Member]
NOTE 1 - BUSINESS ORGANIZATION, NATURE OF OPERATIONS (Details) [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	2,000,000
Notes Issued	$1,000,000
Vaporfection International Inc. [Member]
NOTE 1 - BUSINESS ORGANIZATION, NATURE OF OPERATIONS (Details) [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		260,854
Business Acquisition, Percentage of Voting Interests Acquired		100.00%		100.00%
Contributed Contribution Commitment		1,600,000
Other Commitment		$175,000
Class of Warrant or Rights, Granted		5,000
Number of Subsidiaries			6

NOTE_2_SUMMARY_OF_SIGNIFICANT_

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Detail) (USD $)	12 Months Ended			0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jan. 28, 2015	Sep. 19, 2014	Jul. 21, 2014	Mar. 13, 2015	Jan. 31, 2015	Jan. 30, 2015	Sep. 30, 2014
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Cash, FDIC Insured Amount	$250,000
Advertising Expense	933,627	644,383	806,221
Research and Development Expense	242,232	74,861	176,964
Revenues	621,106	2,062,083	1,176,829
Preferred Stock, Shares Outstanding (in Shares)	3,000,000	3,000,000
Warrants to purchase common stock outstanding	206,480
Debt Instrument, Convertible, Conversion Price	$11.75
Net loss	-16,541,334	-3,791,440	-1,758,237
Net cash used in operating activities	-6,319,400	-3,743,397	-1,444,871
Working capital	-10,000,000
Dispensing Machines [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Revenues	50,000
Convertible Debt [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Debt Instrument, Face Amount	3,750,000				2,500,000	3,500,000
Convertible Debt [Member] | Subsequent Event [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Debt Instrument, Face Amount				1,500,000					1,800,000
Debt Instrument, Convertible, Conversion Price							$1.83	$5
Convertible Debt [Member] | Subsequent Event [Member] | Expected to be raised over the next 18 months [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Expected amount of new equity capital to be raised				5,000,000
Convertible Debt [Member] | Subsequent Event [Member] | Committed to fund as annual SEC filings are completed and the Form S-1 filed with the SEC [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Debt Instrument, Face Amount				3,300,000
Series A Preferred Stock [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Preferred Stock, Shares Outstanding (in Shares)	3,000,000	3,000,000	6,000,000							3,000,000
Preferred Stock, No Par Value (in Dollars per share)	$0.00	$0.00
Convertible Preferred Stock, Shares Issued upon Conversion (in Shares)	15,000,000	15,000,000	30,000,000
Sales Revenue, Net [Member] | Customer C [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration risk, percentage	65.10%
Gross revenue generated	$696,407

NOTE_2_SUMMARY_OF_SIGNIFICANT_1

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedules of Concentration of Risk, by Risk Factor (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Accounts Receivable [Member] | Credit Concentration Risk [Member]
Concentration Risk [Line Items]
Accounts Receivable Amount	$8,774	$339,735
Concentration risk, percentage	100.00%	100.00%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Gross revenue generated	629,132	2,062,083
Concentration risk, percentage	100.00%	100.00%
Customer A [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
Concentration Risk [Line Items]
Accounts Receivable Amount	0	150,000
Concentration risk, percentage	0.00%	44.20%
Customer A [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Gross revenue generated	203,165	325,000
Concentration risk, percentage	29.20%	15.80%
Customer B [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
Concentration Risk [Line Items]
Accounts Receivable Amount	0	115,200
Concentration risk, percentage	0.00%	33.90%
Customer B [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Gross revenue generated	175,000	0
Concentration risk, percentage	25.10%	0.00%
Customer C [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
Concentration Risk [Line Items]
Accounts Receivable Amount	0	0
Concentration risk, percentage	0.00%	0.00%
Customer C [Member] | Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Gross revenue generated	696,407
Concentration risk, percentage	65.10%
Customer C [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Gross revenue generated	75,301	0
Concentration risk, percentage	10.80%	0.00%
Subtotal [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
Concentration Risk [Line Items]
Accounts Receivable Amount	0	265,200
Concentration risk, percentage	0.00%	78.10%
Subtotal [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Gross revenue generated	$453,466	$325,000
Concentration risk, percentage	65.10%	15.80%

NOTE_2_SUMMARY_OF_SIGNIFICANT_2

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Marketable securities	$94,776	$184,800
Derivative Liability	3,691,853	0
Total	3,786,629	184,800
Fair Value, Inputs, Level 1 [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Marketable securities	0	184,800
Derivative Liability	0
Total	0	184,800
Fair Value, Inputs, Level 2 [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Marketable securities	0	0
Derivative Liability	0
Total	0	0
Fair Value, Inputs, Level 3 [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Marketable securities	94,776	0
Derivative Liability	3,691,853
Total	$3,786,629	$0

NOTE_2_SUMMARY_OF_SIGNIFICANT_3

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Abstract]
Beginning balance	$0
Initial recognition of conversion feature	1,885,863
Change in fair value of conversion feature	1,805,990
Ending balance	$3,691,853

NOTE_2_SUMMARY_OF_SIGNIFICANT_4

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Property, Plant and Equipment, Estimated Useful Lives (Detail)	12 Months Ended
	Dec. 31, 2014
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	5 years
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	3 years

NOTE_3_ACQUISITION_Detail

NOTE 3 - ACQUISITION (Detail) (USD $)	12 Months Ended	0 Months Ended	3 Months Ended	12 Months Ended	0 Months Ended
	Dec. 31, 2014	Mar. 22, 2013	Mar. 31, 2014	Dec. 31, 2013	Dec. 29, 2014	Apr. 01, 2013	Dec. 31, 2015
NOTE 3 - ACQUISITION (Details) [Line Items]
Goodwill	$1,260,037			$1,090,037
Legal expense on warrants	280000
Average yield period	3 years
Deferred tax liability, amortizing intangible assets	20,000			0
Vaporfection International Inc. [Member]
NOTE 3 - ACQUISITION (Details) [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired		100.00%				100.00%
Business Acquisition, Equity Interest Issued or Issuable, Description		The Company issued 260,854 warrants to shareholders of VII allowing them to purchase one (1) share of Medbox common stock at $.001 per share beginning April 1, 2013.
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in Shares)		260,854
Fair Value Assumptions, Exercise Price (in Dollars per share)		$4.47
Business Combination, Consideration Transferred, Liabilities Incurred		470,000
Business Combination, Consideration Transferred		1,635,000
Finite-Lived Intangible Asset, Useful Life		10 years
Goodwill		895,000
Increase (Decrease) in Other Accounts Payable and Accrued Liabilities			205,000
Goodwill, Period Increase (Decrease)	10,000			195,000
Warrants exercised	252,812
Business Combination, Contingent Consideration Arrangements, Description		In addition to the above warrants, the purchase agreement and associated consulting contract with the prior management company of the business unit calls for additional shares of common stock to be issued in the event that the performance of the business unit exceeds $11,818,140 of accumulated EBITDA over the subsequent 4 year operating period.
Vaporfection International Inc. [Member] | Finite-Lived Intangible Assets [Member]
NOTE 3 - ACQUISITION (Details) [Line Items]
Deferred tax liability, amortizing intangible assets	160,000
Vaporfection International Inc. [Member] | Scenario Forecast [Member]
NOTE 3 - ACQUISITION (Details) [Line Items]
Goodwill							$1,260,037
Vaporfection International Inc. [Member] | Settlement With Former Shareholders [Member]
NOTE 3 - ACQUISITION (Details) [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in Shares)					50,000

NOTE_3_ACQUISITION_Schedule_of

NOTE 3 - ACQUISITION - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Mar. 22, 2013
NOTE 3 - ACQUISITION (Details) - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Line Items]
Goodwill	$1,260,037	$1,090,037
Vaporfection International Inc. [Member]
NOTE 3 - ACQUISITION (Details) - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Line Items]
Machinery and equipment			70,000
Goodwill			895,000
Total assets acquired			1,635,000
Fair value of liabilities assumed			-469,000
Net fair value			1,166,000
Customer Relationships [Member] | Vaporfection International Inc. [Member]
NOTE 3 - ACQUISITION (Details) - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Line Items]
Intangible assets			314,000
Trademarks and Trade Names [Member] | Vaporfection International Inc. [Member]
NOTE 3 - ACQUISITION (Details) - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Line Items]
Intangible assets			46,000
Noncompete Agreements [Member] | Vaporfection International Inc. [Member]
NOTE 3 - ACQUISITION (Details) - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Line Items]
Intangible assets			23,000
IP and Related Technology [Member] | Vaporfection International Inc. [Member]
NOTE 3 - ACQUISITION (Details) - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Line Items]
Intangible assets			$287,000

NOTE_4_INVESTMENTS_Detail

NOTE 4 - INVESTMENTS (Detail) (USD $)	0 Months Ended
	Feb. 27, 2014	Feb. 08, 2013	Mar. 12, 2013	Jun. 05, 2014	Dec. 31, 2014	Dec. 31, 2013	22-May-13
NOTE 4 - INVESTMENTS (Details) [Line Items]
Investment Owned, at Cost					$0	$1,200,000
Treasury Stock, Value					1,209,600	0
Treasury Stock, Shares (in Shares)					60,000
Bio-Tech Medical Software [Member]
NOTE 4 - INVESTMENTS (Details) [Line Items]
Equity Method Investment, Additional Information		The Company advanced $600,000 upon execution of this agreement for the right to purchase with the remaining balance of $900,000 due and payable in installments at various dates by August 25, 2013. On June 26, 2013, the Company notified Bio-Tech that it was canceling the agreement.
Payments to Acquire Trading Securities Held-for-investment		600,000
Licensing Agreement, Term	5 years
Bio-Tech Medical Software [Member] | Maximum [Member]
NOTE 4 - INVESTMENTS (Details) [Line Items]
Investment, Authorized Shares Available for Purchase (in Shares)		833,333
Equity Method Investment, Ownership Percentage		25.00%
Investment, Purchase Price		1,500,000
MedVend Holdings LLC [Member]
NOTE 4 - INVESTMENTS (Details) [Line Items]
Equity Method Investment, Ownership Percentage			50.00%
Equity Method Investment, Additional Information			In May 2013, the three members of MedVend were named in a lawsuit by that entity's minority shareholders alleging improper conveyance of the three members' ownership interest in MedVend to the Company. Accordingly, also in May 2013, Medbox filed suit against MedVend and the three members of that entity that were involved in the transaction.
Investment Owned, at Cost			4,100,000
MedVend Holdings LLC [Member] | Amount Paid Upon Execution of the Contract [Member]
NOTE 4 - INVESTMENTS (Details) [Line Items]
Payments to Acquire Trading Securities Held-for-investment			300,000
MedVend Holdings LLC [Member] | Amount Disbursed as an Additional Investment [Member]
NOTE 4 - INVESTMENTS (Details) [Line Items]
Payments to Acquire Trading Securities Held-for-investment			300,000
Affiliated Entity [Member]
NOTE 4 - INVESTMENTS (Details) [Line Items]
Treasury Stock, Shares (in Shares)					60,000
Affiliated Entity [Member] | Bio-Tech Medical Software [Member]
NOTE 4 - INVESTMENTS (Details) [Line Items]
Legal Fees				4,800
Stock Repurchased During Period, Shares (in Shares)				30,000
Stock Repurchased During Period, Value				604,800
Affiliated Entity [Member] | MedVend Holdings LLC [Member]
NOTE 4 - INVESTMENTS (Details) [Line Items]
Stock Repurchased During Period, Shares (in Shares)				30,000
Stock Repurchased During Period, Value				604,800
Investment Owned, at Cost							$4,100,000

NOTE_5_INVENTORIES_Schedule_of

NOTE 5 - INVENTORIES - Schedule of Inventory, Current (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Inventory [Line Items]
Work in process and related capitalized costs	$308,867	$242,488
Inventory	961,236	632,986
Deposits on Dispensing Machines [Member]
Inventory [Line Items]
Inventory	325,973	138,423
Vaporizers and Accessories [Member]
Inventory [Line Items]
Inventory	154,930	193,575
Dispensing Machines [Member]
Inventory [Line Items]
Inventory	$171,466	$58,500

NOTE_5_INVENTORIES_Detail

NOTE 5 - INVENTORIES (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Inventory Disclosure [Abstract]
Inventory Write-down	$329,154	$0	$0

NOTE_6_PROPERTY_AND_EQUIPMENT_

NOTE 6 - PROPERTY AND EQUIPMENT - Schedule of Property, Plant and Equipment (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$208,510	$161,781
Less accumulated depreciation	-50,192	-21,123
Property and equipment, net	158,318	140,658
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	22,421	17,192
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	74,404	73,567
Website Development [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	46,922	46,922
Product Development [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$64,763	$24,100

NOTE_6_PROPERTY_AND_EQUIPMENT_1

NOTE 6 - PROPERTY AND EQUIPMENT (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property Plant And Equipment Capitalized Interest Costs [Abstract]
Depreciation expense	$29,000	$37,000	$30,000

NOTE_7_ASSETS_HELD_FOR_RESALE_

NOTE 7 - ASSETS HELD FOR RESALE (Detail) (USD $)	0 Months Ended	3 Months Ended
	Jul. 28, 2014	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
NOTE 7 - ASSETS HELD FOR RESALE (Details) [Line Items]
Assets held for resale			$399,594	$0
Land [Member]
NOTE 7 - ASSETS HELD FOR RESALE (Details) [Line Items]
Proceeds from Sale of Property, Plant, and Equipment		399,594
Debt Instrument, Face Amount	$249,000	$249,000
Debt Instrument, Maturity Date	30-Jan-15	30-Jan-15
Debt Instrument, Interest Rate, Stated Percentage	12.00%	12.00%

NOTE_8_INTANGIBLE_ASSETS_Detai

NOTE 8 - INTANGIBLE ASSETS (Detail) (Vaporfection International Inc. [Member])	Apr. 01, 2013	Mar. 22, 2013
Vaporfection International Inc. [Member]
NOTE 8 - INTANGIBLE ASSETS (Details) [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	100.00%	100.00%

NOTE_8_INTANGIBLE_ASSETS_Sched

NOTE 8 - INTANGIBLE ASSETS - Schedule of Finite-Lived Intangible Assets (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	$792,653	$715,179
Less accumulated amortization	-83,500	-32,750
Intangible assets, net	709,153	682,429
Distribution Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	314,000	314,000
Patented Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	324,653	332,179
Internet Domain Names [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	131,000	46,000
Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	$23,000	$23,000

NOTE_8_INTANGIBLE_ASSETS_Sched1

NOTE 8 - INTANGIBLE ASSETS - Schedule of Finite-Lived Intangible Assets, Estimated Useful Life (Detail)	12 Months Ended
	Dec. 31, 2014
Distribution Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated useful lives	10 years
Internet Domain Names [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated useful lives	10 years
IP and Related Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated useful lives	10 years
Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated useful lives	3 years

NOTE_9_ACCOUNTS_AND_NOTES_RECE

NOTE 9 - ACCOUNTS AND NOTES RECEIVABLE (Detail) (USD $)	0 Months Ended	3 Months Ended	12 Months Ended
	Oct. 20, 2014	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
NOTE 9 - ACCOUNTS AND NOTES RECEIVABLE (Details) [Line Items]
Bad debt expense		$75,000	$207,640
Note Receivable, Face Amount				1,000,000
Note Receivable, Stated Interest Rate, Percentage				5.00%
Note Receivable, Maturity Date		31-Dec-14		10-Dec-18
Increase in notes receivable			40,000
Notes, Loans and Financing Receivable, Net, Current		75,000	0	115,000
Accrued interest paid	6,424		2,834	2,106	4,975
Accounts Receivable [Member]
NOTE 9 - ACCOUNTS AND NOTES RECEIVABLE (Details) [Line Items]
Bad debt expense			132,640
Notes Receivable [Member]
NOTE 9 - ACCOUNTS AND NOTES RECEIVABLE (Details) [Line Items]
Bad debt expense			75,000
Scenario, Adjustment [Member]
NOTE 9 - ACCOUNTS AND NOTES RECEIVABLE (Details) [Line Items]
Notes, Loans and Financing Receivable, Net, Current			$155,000

NOTE_10_MARKETABLE_SECURITIES_

NOTE 10 - MARKETABLE SECURITIES - Shares received as payment from clients (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
NOTE 10 - MARKETABLE SECURITIES AND CUSTOMER DEPOSITS (Details) [Line Items]
Shares received as a payment from client	$0	$184,800
Marketable Securities, Current	94,776	184,800
MJ Holdings [Member]
NOTE 10 - MARKETABLE SECURITIES AND CUSTOMER DEPOSITS (Details) [Line Items]
Marketable Securities, Current	$94,776	$0

NOTE_10_MARKETABLE_SECURITIES_1

NOTE 10 - MARKETABLE SECURITIES (Detail) (USD $)	0 Months Ended	12 Months Ended		0 Months Ended
	Sep. 05, 2014	Dec. 31, 2013	Dec. 31, 2014	19-May-14
NOTE 10 - MARKETABLE SECURITIES AND CUSTOMER DEPOSITS (Details) - Marketable Securities [Line Items]
Marketable Securities, Number of Shares Held as Deposit (in Shares)	7,000,000
Marketable Securities, Value of Shares Held as Customer Deposit	$300,000
Fair Value Inputs, Discount Rate		12.00%
Marketable Securities, Restricted, Current		184,800	0
Class of Warrant or Right, Outstanding (in Shares)			206,480
Endocan [Member]
NOTE 10 - MARKETABLE SECURITIES AND CUSTOMER DEPOSITS (Details) - Marketable Securities [Line Items]
Customer deposit received as collateral description			The last filed financial statements show minimal assets and liabilities of over $1,000,000. Management concluded these factors were indications of impairment, and determined the shares were fully impaired, with the decline being other-than-temporary.
MJ Holdings [Member]
NOTE 10 - MARKETABLE SECURITIES AND CUSTOMER DEPOSITS (Details) - Marketable Securities [Line Items]
Investment, Percentage of Profits Realized from Investment				50.00%
Investment, Term of Investment				6 months
Class of Warrant or Right, Outstanding (in Shares)				33,333
Number of tranches of warrants received for services provided under agreement			6
Class of Warrant or Rights, Exercised (in Shares)			10,825
Class of Warrant or Rights, Fair Value Granted			21,650
Unrealized loss on marketable securities			-73,069

NOTE_10_MARKETABLE_SECURITIES_2

NOTE 10 - MARKETABLE SECURITIES - Schedule of Marketable Securities (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Jun. 19, 2014	19-May-14
NOTE 10 - MARKETABLE SECURITIES AND CUSTOMER DEPOSITS (Details) - Schedule of Marketable Securities [Line Items]
Warrant Fair Value	$73,126	$203,165	($94,719)
Fair Value at Conversion	-35,320
Warrant #1 [Member]
NOTE 10 - MARKETABLE SECURITIES AND CUSTOMER DEPOSITS (Details) - Schedule of Marketable Securities [Line Items]
Warrant Fair Value	0	95,866	-94,719
Fair Value at Conversion	-1,147
Warrant #2 [Member]
NOTE 10 - MARKETABLE SECURITIES AND CUSTOMER DEPOSITS (Details) - Schedule of Marketable Securities [Line Items]
Warrant Fair Value	8,179	2,666	0
Fair Value at Conversion	5,513
Warrant #3 [Member]
NOTE 10 - MARKETABLE SECURITIES AND CUSTOMER DEPOSITS (Details) - Schedule of Marketable Securities [Line Items]
Warrant Fair Value	8,920	53,867	0
Fair Value at Conversion	-44,947
Warrant #4 [Member]
NOTE 10 - MARKETABLE SECURITIES AND CUSTOMER DEPOSITS (Details) - Schedule of Marketable Securities [Line Items]
Warrant Fair Value	10,318	30,600	0
Fair Value at Conversion	-20,282
Warrant # 5 [Member]
NOTE 10 - MARKETABLE SECURITIES AND CUSTOMER DEPOSITS (Details) - Schedule of Marketable Securities [Line Items]
Warrant Fair Value	20,053	7,133	0
Fair Value at Conversion	12,920
Warrant # 6 [Member]
NOTE 10 - MARKETABLE SECURITIES AND CUSTOMER DEPOSITS (Details) - Schedule of Marketable Securities [Line Items]
Warrant Fair Value	25,656	13,033	0
Fair Value at Conversion	$12,623

NOTE_10_MARKETABLE_SECURITIES_3

NOTE 10 - MARKETABLE SECURITIES - Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques (Detail) (USD $)	0 Months Ended	12 Months Ended
	19-May-14	Dec. 31, 2014	19-May-14
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Number of warrants/shares (in Shares)		206,480
Warrant #1 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price, $	$8.69		$8.69
Exercise price, $	$6.42		$6.42
Time to maturity, Years	6 months
Annual risk-free rate, %	0.05%
Annualized volatility, %	70.00%
Black-Scholes Value per warrant, $	$2.88		$2.88
Number of warrants/shares (in Shares)	33,333		33,333
Total value of warrants/shares, $ (in Dollars)	$95,866		$95,866
Warrant #2 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price, $	$4	$2	$4
Exercise price, $	$8.45	$8.45	$8.45
Time to maturity, Years	6 months	1 year
Annual risk-free rate, %	0.05%	0.22%
Annualized volatility, %	70.00%	120.00%
Black-Scholes Value per warrant, $	$0.08	$0.25	$0.08
Number of warrants/shares (in Shares)	33,333	33,333	33,333
Total value of warrants/shares, $ (in Dollars)	2,666	8,179	2,666
Warrant #3 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price, $	$8	$2	$8
Exercise price, $	$7.87	$7.87	$7.87
Time to maturity, Years	6 months	1 year
Annual risk-free rate, %	0.05%	0.22%
Annualized volatility, %	70.00%	120.00%
Black-Scholes Value per warrant, $	$1.62	$0.27	$1.62
Number of warrants/shares (in Shares)	33,333	33,333	33,333
Total value of warrants/shares, $ (in Dollars)	53,867	8,920	53,867
Warrant #4 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price, $	$6.15	$2	$6.15
Exercise price, $	$6.95	$6.95	$6.95
Time to maturity, Years	6 months	1 year
Annual risk-free rate, %	0.05%	0.22%
Annualized volatility, %	70.00%	120.00%
Black-Scholes Value per warrant, $	$0.92	$0.31	$0.92
Number of warrants/shares (in Shares)	33,333	33,333	33,333
Total value of warrants/shares, $ (in Dollars)	30,600	10,318	30,600
Warrant # 5 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price, $	$2.01	$2	$2.01
Exercise price, $	$3.53	$3.53	$3.53
Time to maturity, Years	1 year	1 year
Annual risk-free rate, %	0.04%	0.22%
Annualized volatility, %	70.00%	120.00%
Black-Scholes Value per warrant, $	$0.21	$0.60	$0.21
Number of warrants/shares (in Shares)	33,333	33,333	33,333
Total value of warrants/shares, $ (in Dollars)	7,133	20,053	7,133
Warrant # 6 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price, $	$2.02	$2	$2.02
Exercise price, $	$2.56	$2.56	$2.56
Time to maturity, Years	1 year	1 year
Annual risk-free rate, %	0.11%	0.22%
Annualized volatility, %	70.00%	120.00%
Black-Scholes Value per warrant, $	$0.39	$0.77	$0.39
Number of warrants/shares (in Shares)	33,333	33,333	33,333
Total value of warrants/shares, $ (in Dollars)	$13,033	$25,656	$13,033

NOTE_11_CUSTOMER_DEPOSITS_Cust

NOTE 11 - CUSTOMER DEPOSITS - Customer Advances and Deposits, Current (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Customer Advances and Deposits, Current [Abstract]
Advance payments from customers	$1,450,770	$710,225
Advance payments for vaporizers	75,038	75,636
Total customer deposits	$1,525,808	$785,861

NOTE_12_SHORTTERM_DEBT_Detail

NOTE 12 - SHORT-TERM DEBT (Detail) (USD $)	12 Months Ended	0 Months Ended	3 Months Ended
	Dec. 31, 2014	Jul. 28, 2014	Sep. 30, 2014
NOTE 12 - SHORT-TERM DEBT (Details) [Line Items]
Repayments of Notes Payable	$75,000
Notes Payable, Other Payables [Member]
NOTE 12 - SHORT-TERM DEBT (Details) [Line Items]
Debt Instrument, Face Amount	12,434
Debt Instrument, Interest Rate, Stated Percentage	5.99%
Debt Instrument, Date of First Required Payment	5-Sep-14
Debt Instrument, Maturity Date	5-May-15
Debt Instrument, Periodic Payment, Interest	2,524
Land [Member]
NOTE 12 - SHORT-TERM DEBT (Details) [Line Items]
Debt Instrument, Face Amount		$249,000	$249,000
Debt Instrument, Interest Rate, Stated Percentage		12.00%	12.00%
Debt Instrument, Date of First Required Payment		1-Aug-14
Debt Instrument, Date of Final Required Payment		1-Jan-15
Debt Instrument, Maturity Date		30-Jan-15	30-Jan-15
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Maximum		18.00%
Debt Instrument, Interest Rate, late charge		5.00%

NOTE_13_CONVERTIBLE_NOTES_PAYA

NOTE 13 - CONVERTIBLE NOTES PAYABLE AND DERIVATIVE LIABILITY (Detail) (USD $)

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Nov. 24, 2014

Sep. 24, 2014

Sep. 19, 2014

Aug. 25, 2014

Jul. 21, 2014

Jan. 31, 2015

Aug. 26, 2014

Sep. 26, 2014

Mar. 13, 2015

Jan. 30, 2015

Jan. 28, 2015

NOTE 13 - CONVERTIBLE NOTES PAYABLE AND DERIVATIVE LIABILITY (Details) [Line Items]

Proceeds from Convertible Debt

$3,475,000

$0

$0

Debt Instrument, Convertible, Conversion Price

$11.75

Debt discount

1,225,573

Change in fair value of derivative liabilities

-1,805,990

0

0

Convertible Debt [Member]

NOTE 13 - CONVERTIBLE NOTES PAYABLE AND DERIVATIVE LIABILITY (Details) [Line Items]

Debt Instrument, Maturity Date

19-Sep-15

21-Jul-15

Debt Instrument, Face Amount

3,750,000

2,500,000

3,500,000

Proceeds from Convertible Debt

250,000

500,000

1,000,000

1,000,000

1,000,000

Debt Instrument, Interest Rate, Stated Percentage

5.00%

10.00%

Debt Instrument, Payment Terms

Repayment, including accrued principal and accrued interest, due in nine monthly installments, commencing the fourth month after issuance.

Repayment, including accrued principal and accrued interest, beginning on the eleventh day of the fourth month after issuance and will continue on the eleventh day of each following 8 successive months thereafter.

Debt Instrument, Description

In connection with each of the purchase agreements, the Company entered into a registration rights agreement with the respective investors, pursuant to which the Company agreed to file a registration statement for the resale of the shares of common stock issuable upon conversion of, or payable as principal and interest on, the respective debentures, within 45 days of the initial closing date under each agreement, and to have such registration statements declared effective within 120 days of the initial closing dates of each purchase agreement. The registration statement was not declared effective within 120 days, and the amortization payment conversion rate was adjusted accordingly.

The second closing, of $1,500,000, is to occur within 2 days of the effective date of the registration statement filed by the Company for the resale of the shares of common stock issuable upon conversion of the September 2014 Purchase Agreement Debentures.

Debt Instrument, Convertible, Terms of Conversion Feature

Beginning four months (as subsequently amended) after the initial closing, the Company will begin making amortization payments on the debt in cash, prompting a 30% premium or, at their option and subject to certain conditions, in shares of common stock valued at 70% of the lowest volume weighted average price of the common stock for the 20 prior trading days. However, in the event the registration statement filed by the Company in connection with the respective purchase agreements is not effective within 120 days of the initial closing date under the July 2014 Purchase Agreement and 120 days of the initial closing date under the September 2014 Purchase Agreement, the July 2014 Purchase Agreement Debenturesb and the September 2014 Purchase Agreement Debenturesb, respectively, conversion rate will be, during the period commencing 120 days after the initial closing date until the registration statement is effective, equal to 63% of the lowest volume weighted average price of the common stock for the 20 prior trading days. If the aforementioned registration statement is not effective within 160 days of the initial closing date, each of the debenturesb conversion rate will be, during the period commencing 160 days after the initial closing date until the registration statement is effective, equal to 60% of the lowest volume weighted average price of the common stock for the 20 prior trading days.

Debt discount

275,000

Derivative Liability

1,885,000

Convertible Debt [Member] | Subsequent Event [Member]

NOTE 13 - CONVERTIBLE NOTES PAYABLE AND DERIVATIVE LIABILITY (Details) [Line Items]

Debt Instrument, Face Amount

1,800,000

1,500,000

Debt Instrument, Convertible, Conversion Price

$5

$1.83

Conversion, percentage of weighted average price

51.00%

Consecutive Trading Days

20 days

Convertible Debt [Member] | Debt Instrument, Tranche Two [Member]

NOTE 13 - CONVERTIBLE NOTES PAYABLE AND DERIVATIVE LIABILITY (Details) [Line Items]

Debt Instrument, Face Amount

1,500,000

1,000,000

Proceeds from Convertible Debt

1,000,000

Convertible Debt [Member] | Debt Instrument, Tranche One [Member]

NOTE 13 - CONVERTIBLE NOTES PAYABLE AND DERIVATIVE LIABILITY (Details) [Line Items]

Debt Instrument, Face Amount

1,000,000

1,000,000

Proceeds from Convertible Debt

1,000,000

Convertible Debt [Member] | Debt Instrument, Tranche Three [Member]

NOTE 13 - CONVERTIBLE NOTES PAYABLE AND DERIVATIVE LIABILITY (Details) [Line Items]

Debt Instrument, Face Amount

1,000,000

Proceeds from Convertible Debt

500,000

Convertible Debt [Member] | Debt Instrument, Tranche Four [Member]

NOTE 13 - CONVERTIBLE NOTES PAYABLE AND DERIVATIVE LIABILITY (Details) [Line Items]

Proceeds from Convertible Debt

$250,000

NOTE_14_PREPAID_EXPENSES_AND_O

NOTE 14 - PREPAID EXPENSES AND OTHER CURRENT ASSETS - Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Prepaid expenses and other current assets
Rent	$0	$3,962
Directors & officers insurance	31,491	0
Professional fees	10,000	52,739
Other vendors	24,729	32,540
Prepaid expenses and other current assets	$66,220	$89,241

NOTE_15_RESTRICTED_STOCK_AND_R

NOTE 15 - RESTRICTED STOCK AND RESTRICTED STOCK UNITS ("RSUs") (Detail) (USD $)	0 Months Ended			12 Months Ended	1 Months Ended	3 Months Ended	0 Months Ended
	Sep. 08, 2014	Aug. 21, 2014	Jul. 23, 2014	Dec. 31, 2014	Oct. 31, 2014	Sep. 30, 2014	Apr. 01, 2015
NOTE 15 - RESTRICTED STOCK AND RESTRICTED STOCK UNITS ("RSUs") (Details) [Line Items]
Employment Agreement, Term			2 years
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award			Under the Equity Incentive Plan adopted by the Company, in the amount of the greater (by value) of 50,000 shares of common stock or $500,000 of common stock based on the volume weighted average price for the 30 day period prior to the date of the grant.
Stock Issued During Period, Value, Restricted Stock Award, Gross				$970,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period			1 year
Number of Board Members	2	2
Restricted Stock [Member]
NOTE 15 - RESTRICTED STOCK AND RESTRICTED STOCK UNITS ("RSUs") (Details) [Line Items]
Stock Issued During Period, Value, Restricted Stock Award, Gross		3,607,500
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		346,875		346,875
Restricted Stock Units (RSUs) [Member]
NOTE 15 - RESTRICTED STOCK AND RESTRICTED STOCK UNITS ("RSUs") (Details) [Line Items]
Stock Issued During Period, Value, Restricted Stock Award, Gross		1,267,500
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted (in Shares)					50,000	70,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		121,875		422,980
Number of shares underlying restricted stock		121,875
Restricted Stock Units (RSUs) [Member] | Board Of Directors [Member]
NOTE 15 - RESTRICTED STOCK AND RESTRICTED STOCK UNITS ("RSUs") (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period					19,452
Restricted Stock Units (RSUs) [Member] | Board Of Directors [Member] | Scenario Forecast [Member]
NOTE 15 - RESTRICTED STOCK AND RESTRICTED STOCK UNITS ("RSUs") (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period							100,000
Restricted Stock Units (RSUs) [Member] | Additional Award [Member]
NOTE 15 - RESTRICTED STOCK AND RESTRICTED STOCK UNITS ("RSUs") (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted (in Shares)						20,000

NOTE_15_RESTRICTED_STOCK_AND_R1

NOTE 15 - RESTRICTED STOCK AND RESTRICTED STOCK UNITS ("RSUs") - Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity (Detail) (USD $)	0 Months Ended	12 Months Ended
	Aug. 21, 2014	Dec. 31, 2014
Restricted Stock [Member]
NOTE 15 - RESTRICTED STOCK AND RESTRICTED STOCK UNITS ("RSUs") (Details) - Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Line Items]
Restricted stock non-vested at beginning of period		0
Restricted stock granted	346,875	346,875
Restricted stock vested		-178,125
Restricted stock forfeited		0
Restricted stock non-vested at end of period		168,750
Restricted stock non-vested at beginning of period		$0
Restricted stock granted		$10.40
Restricted stock vested		$10.40
Restricted stock forfeited		$0
Restricted stock non-vested at end of period		$10.40
Restricted Stock Units (RSUs) [Member]
NOTE 15 - RESTRICTED STOCK AND RESTRICTED STOCK UNITS ("RSUs") (Details) - Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Line Items]
Restricted stock non-vested at beginning of period		0
Restricted stock granted	121,875	422,980
Restricted stock vested		-223,396
Restricted stock forfeited		0
Restricted stock non-vested at end of period		199,584
Restricted stock non-vested at beginning of period		$0
Restricted stock granted		$10.84
Restricted stock vested		$11.19
Restricted stock forfeited		$0
Restricted stock non-vested at end of period		$10.70

NOTE_15_RESTRICTED_STOCK_AND_R2

NOTE 15 - RESTRICTED STOCK AND RESTRICTED STOCK UNITS ("RSUs") - Allocation of Recognized Period Costs (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation	$4,415,799	$0	$0
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation	663,262
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation	$3,752,537

NOTE_16_RELATED_PARTY_TRANSACT

NOTE 16 - RELATED PARTY TRANSACTIONS (Detail) (USD $)

0 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

Sep. 08, 2014

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Oct. 31, 2014

Sep. 30, 2014

Aug. 15, 2014

Jul. 21, 2014

Jan. 01, 2012

Sep. 30, 2014

Nov. 01, 2014

Dec. 31, 2014

Nov. 30, 2014

Mar. 31, 2014

Oct. 17, 2014

Oct. 28, 2013

Sep. 20, 2013

Mar. 28, 2014

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Notes Payable, Related Parties, Current

$678,877

$111,794

678,877

Escrow Deposit

400,476

0

400,476

Stock Issued During Period, Shares, Share-based Compensation, Gross (in Shares)

346,875

Contribution from related parties

0

810,000

561,000

Deposits and other assets

104,726

98,726

104,726

Restricted Stock Units (RSUs) [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted (in Shares)

50,000

70,000

Additional Award [Member] | Restricted Stock Units (RSUs) [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted (in Shares)

20,000

Affiliated Entity [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Manufacturing Costs

480,000

510,000

Escrow Deposit

190,400

Affiliated Entity [Member] | Vincent Chase Inc. [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Debt Instrument, Face Amount

100,000

100,000

150,000

Debt Instrument, Interest Rate, Stated Percentage

0.00%

Debt Instrument, Maturity Date, Description

payable on demand

Equity Method Investment, Ownership Percentage

100.00%

100.00%

Related Party Transaction, Amounts of Transaction

168,625

262,500

230,706

Number of Promissory Notes

2

Due to Related Parties, Current

111,794

Affiliated Entity [Member] | PVM International Inc. (PVMI) [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Notes Payable, Related Parties, Current

775,038

Debt Instrument, Face Amount

1,000,000

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Debt Instrument, Maturity Date, Description

due on demand

Equity Method Investment, Ownership Percentage

100.00%

100.00%

100.00%

Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in Shares)

4,000,000

Debt Instrument, Collateral

secured with 1,000,000 shares of the Company's common stock

Number of Promissory Notes

4

Due to Related Parties, Current

388,477

388,477

Repayments of Related Party Debt

75,000

Affiliated Entity [Member] | PVM International Inc. (PVMI) [Member] | Note Payable #1 [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Debt Instrument, Face Amount

250,000

250,000

Affiliated Entity [Member] | PVM International Inc. (PVMI) [Member] | Note Payable #2 [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Debt Instrument, Face Amount

100,000

100,000

Affiliated Entity [Member] | PVM International Inc. (PVMI) [Member] | Note Payable 3 [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Debt Instrument, Face Amount

500,000

500,000

Affiliated Entity [Member] | PVM International Inc. (PVMI) [Member] | Note Payable #4 [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Debt Instrument, Face Amount

375,000

375,000

Affiliated Entity [Member] | Dr. Bruce Consulting [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Equity Method Investment, Ownership Percentage

100.00%

100.00%

Related Party Transaction, Amounts of Transaction

43,750

133,991

500,000

Affiliated Entity [Member] | Kind Clinics, LLC [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Equity Method Investment, Ownership Percentage

100.00%

Related Party Transaction, Amounts of Transaction

113,613

Former Chief Executive Officer [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Stock Issued During Period, Shares, Share-based Compensation, Gross (in Shares)

20,000

Stock Issued During Period, Value, Share-based Compensation, Forfeited

20,000

Former Chief Executive Officer [Member] | Restricted Stock Units (RSUs) [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted (in Shares)

70,000

50,000

Former Chief Executive Officer [Member] | Additional Award [Member] | Restricted Stock Units (RSUs) [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted (in Shares)

20,000

Related Party And Shareholder [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Related Party Transaction, Amounts of Transaction

150,000

Deposits and other assets

400,000

500,000

Investor [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Notes Payable, Related Parties, Current

94,000

Debt Instrument, Face Amount

$125,000

Debt Instrument, Interest Rate, Stated Percentage

0.00%

Debt Instrument, Maturity Date, Description

due on demand

NOTE_17_STOCKHOLDERS_EQUITY_De

NOTE 17 - STOCKHOLDER'S EQUITY (Detail) (USD $)	0 Months Ended				3 Months Ended	12 Months Ended			1 Months Ended		3 Months Ended	1 Months Ended	0 Months Ended
	Sep. 08, 2014	Aug. 21, 2014	Feb. 03, 2014	Dec. 18, 2013	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jan. 31, 2014	Nov. 30, 2011	Dec. 31, 2012	Jan. 31, 2013	Jan. 01, 2012	Jun. 05, 2014	Oct. 07, 2014	Apr. 01, 2013	Mar. 22, 2013	Sep. 30, 2014
NOTE 17 - STOCKHOLDER'S EQUITY (Details) [Line Items]
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)					$0.00	$0.00	$0.00
Preferred Stock, Shares Outstanding					3,000,000	3,000,000	3,000,000
Treasury Stock, Shares					60,000	60,000
Proceeds from Issuance of Common Stock (in Dollars)						$2,442,859	$4,486,541	$858,415
Dividends Payable, Nature				two-for-one (2:1)
Common Stock Dividends, Shares			14,762,875
Stock Issued During Period, Shares, Share-based Compensation, Gross	346,875
Number of Board Members	2	2
Stock Issued During Period, shares, as a payment of certain accounts payables					52,892
Stock Issued During Period, value, as a payment of certain accounts payables					316,065	316,065	119,553
Stock value to be received								153,250			153,250
Shares to be received								74,100			74,100
Vaporfection International Inc. [Member]
NOTE 17 - STOCKHOLDER'S EQUITY (Details) [Line Items]
Non-cash additions to equity from the issuances of warrants and common stock in connection with acquisition							1,285,553
Business Acquisition, Percentage of Voting Interests Acquired																100.00%	100.00%
Common Stock [Member]
NOTE 17 - STOCKHOLDER'S EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, New Issues						485,830	2,115,100	2,463,366
Stock Issued During Period, shares, as a payment of certain accounts payables						54,392	43,506
Stock Issued During Period, value, as a payment of certain accounts payables						54	44
Non-cash additions to equity from the issuances of warrants and common stock in connection with acquisition								4,000
Shares of common stock sold								2,463,000
Proceed from issuance of common stock								858,000
Issuance of common stock for acquisition PVMI (in Shares)								4,000,000
Common Stock Issuance [Member]
NOTE 17 - STOCKHOLDER'S EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, New Issues							2,115,100		485,830
Sale of Stock, Price Per Share (in Dollars per share)							$2.23		$5
Proceeds from Issuance of Common Stock (in Dollars)							4,486,541		2,427,859
Series A Preferred Stock [Member]
NOTE 17 - STOCKHOLDER'S EQUITY (Details) [Line Items]
Preferred Stock, Shares Outstanding					3,000,000	3,000,000	3,000,000	6,000,000			6,000,000							3,000,000
Special voting right										The Series A Preferred Stock has special voting rights when voting as a class with the Common Stock as follows: (i) the holders of Series A Preferred Stock shall have such number of votes as is determined by multiplying (a) the number of shares of Series A Preferred Stock held by such holder, (b) the number of issued and outstanding shares of the Corporationbs Series A Preferred Stock and Common Stock (collectively, the bCommon Stockb) on a Fully-Diluted Basis (as hereinafter defined), as of the record date for the vote, or, if no such record date is established, as of the date such vote is taken or any written consent of stockholders is solicited, and (c) 0.00000025; and (ii) the holders of Common Stock shall have one vote per share of Common Stock held as of such date. bFully-Diluted Basisb mean that the total number of issued and outstanding shares of the Companybs Common Stock shall be calculated to include (a) the shares of Common Stock issuable upon exercise and/or conversion of all of the following securities (collectively, bCommon Stock Equivalentsb): all outstanding (a) securities convertible into or exchangeable for Common Stock, whether or not then convertible or exchangeable (collectively, bConvertible Securitiesb), (b) subscriptions, rights, options and warrants to purchase shares of Common Stock, whether or not then exercisable (collectively, bOptionsb), and (c) securities convertible into or exchangeable or exercisable for Options or Convertible Securities and any such underlying Options and/or Convertible Securities.
Series A Preferred Stock [Member] | Stock Issued to Founder and Shareholder [Member]
NOTE 17 - STOCKHOLDER'S EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, New Issues										6,000,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)										0.001
Convertible Preferred Stock, Terms of Conversion										converted to common stock at a ratio of 1 (one) share of Series A Preferred Stock to 5 (five) shares of common stock
Series A Preferred Stock [Member] | Stock Issued To Shareholder [Member]
NOTE 17 - STOCKHOLDER'S EQUITY (Details) [Line Items]
Stock Repurchased During Period, Shares											3,000,000
Series A Preferred Stock [Member] | Stock Issued to Founder [Member]
NOTE 17 - STOCKHOLDER'S EQUITY (Details) [Line Items]
Stock Repurchased and Retired During Period, Shares												3,000,000
Affiliated Entity [Member]
NOTE 17 - STOCKHOLDER'S EQUITY (Details) [Line Items]
Treasury Stock, Shares					60,000	60,000
Affiliated Entity [Member] | PVM International Inc. (PVMI) [Member]
NOTE 17 - STOCKHOLDER'S EQUITY (Details) [Line Items]
Issuance of common stock for acquisition PVMI (in Shares)													4,000,000
Business Acquisition, Percentage of Voting Interests Acquired													100.00%
Affiliated Entity [Member] | Bio-Tech Medical Software [Member]
NOTE 17 - STOCKHOLDER'S EQUITY (Details) [Line Items]
Stock Repurchased During Period, Shares														30,000
Stock Repurchased During Period, Value (in Dollars)														604,800
Affiliated Entity [Member] | MedVend Holdings LLC [Member]
NOTE 17 - STOCKHOLDER'S EQUITY (Details) [Line Items]
Stock Repurchased During Period, Shares														30,000
Stock Repurchased During Period, Value (in Dollars)														$604,800
Board Member [Member]
NOTE 17 - STOCKHOLDER'S EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross	93,751														84,374

NOTE_18_INCOME_TAXES_Significa

NOTE 18 - INCOME TAXES - Significant Components of Deferred Tax Assets and Liabilities (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets
Customer deposits	$295,000	$293,000
Deferred revenue	35,000	0
Share based compensation	1,760,000	0
NOL carryforward	5,400,000	2,377,000
Total deferred tax asset	7,490,000	2,670,000
Deferred tax liabilities:
Deferred revenue	0	285,000
Intangible asset amortization	20,000	0
Total deferred tax liabilities	20,000	285,000
Net deferred tax assets	7,470,000	2,385,000
Less: Valuation allowance	-7,470,000	-2,385,000
Net	$0	$0

NOTE_18_INCOME_TAXES_Additiona

NOTE 18 - INCOME TAXES - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Valuation allowance, change in amount	$5,085,000
Net operating loss carryforwards	$13,510,000

NOTE_18_INCOME_TAXES_Reconcili

NOTE 18 - INCOME TAXES - Reconciliation of Statutory Rate and Effective Rate for Provisions for Income Taxes (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Federal Tax statutory rate	34.00%	34.00%	34.00%
State tax statutory rate	6.00%	8.84%	8.84%
Permanent differences	-6.72%	0.00%
Valuation allowance	-33.28%	-42.84%	-42.84%
Effective rate	0.00%	0.00%	0.00%

NOTE_19_COMMITMENTS_AND_CONTIN

NOTE 19 - COMMITMENTS AND CONTINGENCIES (Detail) (USD $)

0 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

Oct. 17, 2014

Jul. 23, 2014

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 17, 2013

Jul. 22, 2014

8-May-14

Sep. 30, 2014

Jul. 31, 2014

Jun. 05, 2014

Oct. 16, 2014

22-May-13

Jul. 01, 2014

Aug. 01, 2011

Oct. 13, 2014

Oct. 31, 2014

Jan. 31, 2015

Mar. 12, 2013

Mar. 31, 2013

Agreement

Commitments And Contingencies [Line Items]

Operating Leases, Rent Expense

$204,726

$139,330

$124,727

Payments to Acquire Real Estate

50,000

399,594

0

0

Real Estate, Purchase Price

2,120,000

Escrow Deposit

400,476

0

Employment Agreement, Term

2 years

Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award

Under the Equity Incentive Plan adopted by the Company, in the amount of the greater (by value) of 50,000 shares of common stock or $500,000 of common stock based on the volume weighted average price for the 30 day period prior to the date of the grant.

Investment Owned, at Cost

0

1,200,000

Vaporfection International Inc. [Member]

Commitments And Contingencies [Line Items]

Operating Leases, Rent Expense, Minimum Rentals

1,981

Lessee Leasing Arrangements, Operating Leases, Term of Contract

1 year

MedVend Holdings LLC [Member]

Commitments And Contingencies [Line Items]

Equity Method Investment, Ownership Percentage

50.00%

Investment Owned, at Cost

4,100,000

Land and Building [Member]

Commitments And Contingencies [Line Items]

Operating Leases, Rent Expense, Minimum Rentals

20,000

7,400

Lessee Leasing Arrangements, Operating Leases, Term of Contract

5 years

5 years

Security Deposit

30,000

Real Estate, Purchase Price

399,594

Notes Issued

249,000

Potential Real Estate Purcahse Foreclosed Upon [Member] | Land and Building [Member]

Commitments And Contingencies [Line Items]

Number of Real Estate Purchase Agreements

1

Proceeds from Other Deposits

10,000

Affiliated Entity [Member]

Commitments And Contingencies [Line Items]

Escrow Deposit

190,400

Affiliated Entity [Member] | MedVend Holdings LLC [Member]

Commitments And Contingencies [Line Items]

Claims damages

500,000

Stock Repurchased During Period, Shares (in Shares)

30,000

Investment Owned, at Cost

4,100,000

Legal fees accrued

500,000

Plaintiff past due balance

550,000

Affiliated Entity [Member] | MedVend Holdings LLC [Member] | Funded at the Closing of the Purchase Agreement Amendment [Member]

Commitments And Contingencies [Line Items]

Equity Method Investment, Ownership Percentage

50.00%

Chief Financial Officer [Member]

Commitments And Contingencies [Line Items]

Other Commitments, Description

Pursuant to the Employment Agreement, the Company agreed to engage Mr. Mitchell, and Mr. Mitchell agreed to serve as the Company's Chief Financial Officer, for a two-year term, which term will automatically be extended for successive additional one-year terms, unless either party provides written notice to the other 90 days prior to the expiration of the initial term or any successive term, that the Employment Agreement will not be renewed.

Employment Agreement, Term

2 years

Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award

Mitchell will also be entitled to an award of restricted stock units, to be issued within 90 days of the effective date of the Employment Agreement, under the Company's Equity Incentive Plan, in the amount of 7,500 shares of common stock each calendar quarter Mr. Mitchell serves as Chief Financial Officer of the Company.

Chief Financial Officer [Member] | Subsequent Event [Member]

Commitments And Contingencies [Line Items]

Employee Agreement, Description

Termination by the Company within 365 days of a Change of Control (as defined in the Employment Agreement) in the absence of Cause will conclusively be deemed a termination by the Company without Cause.

Vice President [Member] | Restricted Stock Units (RSUs) [Member]

Commitments And Contingencies [Line Items]

Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures (in Shares)

19,452

Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in Shares)

100,000

Amount Paid Upon Execution of the Contract [Member] | MedVend Holdings LLC [Member]

Commitments And Contingencies [Line Items]

Payments to Acquire Trading Securities Held-for-investment

300,000

Amount Disbursed as an Additional Investment [Member] | MedVend Holdings LLC [Member]

Commitments And Contingencies [Line Items]

Payments to Acquire Trading Securities Held-for-investment

300,000

Convertible Debt [Member]

Commitments And Contingencies [Line Items]

Debt Instrument, Payment Terms

Due to the restatement discussed above, the registration statement has been delayed. As a result of the withdraw of the Form S-1, in January 2015 the Company agreed with the lenders to adjust the conversion rate for the amortization payments and reduced the volume weighted average price for 20 days prior to the issuance to 51%. See Note 20 Subsequent Events for purchase agreement modifications finalized in January 2015.

Office Lease, West Hollywood, California [Member]

Commitments And Contingencies [Line Items]

Operating Lease, Rent Increase, Percent

3.00%

Operating Leases, Rent Expense

14,828

Lease Expiration Date

30-Jun-17

Operating Leases, Rent Expense, Minimum Rentals

14,397

Virtual offices/meeting spaces in Seattle and Illinois [Member]

Commitments And Contingencies [Line Items]

Operating Leases, Rent Expense, Minimum Rentals

705

Description of Lessee Leasing Arrangements, Operating Leases

month to month basis

Agreement One [Member] | Land and Building [Member]

Commitments And Contingencies [Line Items]

Escrow Deposits Related to Property Sales

930,000

Payments to Acquire Real Estate

26,830,000

Agreement One [Member] | Forfeiture Of Earnest Money On Potential Purchase Of Real Estate [Member] | Land and Building [Member]

Commitments And Contingencies [Line Items]

Real Estate, Purchase Price

3,195,000

Number of Real Estate Purchase Agreements

3

Earnest Money Forfeited

140,000

Monthly Advisory and Consulting Service Fee [Member]

Commitments And Contingencies [Line Items]

Other Commitments, Description

The monthly consulting fee was reduced to $12,500 per month if Mr. Mehdizadeh is engaged in trading any of the Company's securities at any time within the preceding 30 day period.

Consulting agreement

12,375

Other Commitment

10,000

Hourly Advisory And Consulting Service Fee [Member]

Commitments And Contingencies [Line Items]

Other Commitment

200

Advisory And Consulting Services [Member] | Restricted Stock Units (RSUs) [Member]

Commitments And Contingencies [Line Items]

Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures (in Shares)

100,000

Annual Salary [Member] | Chief Financial Officer [Member]

Commitments And Contingencies [Line Items]

Other Commitment

190,000

Living Expenses [Member] | Chief Financial Officer [Member]

Commitments And Contingencies [Line Items]

Other Commitment

2,500

Annual Bonus [Member] | Chief Financial Officer [Member] | Maximum [Member]

Commitments And Contingencies [Line Items]

Percentage of bonus on base salary

35.00%

Annual Cash Bonus [Member] | Chief Financial Officer [Member]

Commitments And Contingencies [Line Items]

Percentage of bonus in cash

50.00%

Office Facilities Lease, West Hills, California [Member]

Commitments And Contingencies [Line Items]

Operating Leases, Rent Expense, Minimum Rentals

1,300

Office Facilities Lease, Scottsdale, Arizona [Member]

Commitments And Contingencies [Line Items]

Operating Leases, Rent Expense, Minimum Rentals

1,420

Agreement Two [Member] | Land and Building [Member]

Commitments And Contingencies [Line Items]

Escrow Deposits Related to Property Sales

685,000

Payments to Acquire Real Estate

21,515,000

Earnest Money Forfeited

235,757

Proceeds from Other Deposits

419,167

Agreement Two [Member] | Land and Building [Member] | Subsequent Event [Member]

Commitments And Contingencies [Line Items]

Proceeds from Other Deposits

$30,076

NOTE_19_COMMITMENTS_AND_CONTIN1

NOTE 19 - COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Rental Payments for Operating Leases (Detail) (USD $)	Dec. 31, 2014
Building [Member]
Property Subject to or Available for Operating Lease [Line Items]
2015	$177,936
2016	177,936
2017	88,968
2018	0
2019	0
Total	444,840
Land and Building [Member]
Property Subject to or Available for Operating Lease [Line Items]
2015	88,800
2016	88,800
2017	88,800
2018	88,800
2019	29,600
Total	$384,800

NOTE_19_COMMITMENTS_AND_CONTIN2

NOTE 19 - COMMITMENTS AND CONTINGENCIES - Schedule of Real Estate Properties (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
Real Estate Properties [Line Items]
Purchase price	$2,120,000
Net escrow balance	400,476
Additional rents/fees paid to extend closing date	9,808
Property 1 [Member]
Real Estate Properties [Line Items]
Purchase price	820,000
Closing date	3/31/15
Net escrow balance	55,000
Date escrow opened	6/28/14
Additional rents/fees paid to extend closing date	9,808
Property 2 [Member]
Real Estate Properties [Line Items]
Purchase price	1,300,000
Closing date	3/30/15
Net escrow balance	50,000
Date escrow opened	10/17/14
Property 3 [Member]
Real Estate Properties [Line Items]
Purchase price	0
Net escrow balance	265,400
Date escrow opened	7/21/14
Additional rents/fees paid to extend closing date	0
Escrow deposits to be refunded [Member]
Real Estate Properties [Line Items]
Net escrow balance	$30,076

NOTE_20_SUBSEQUENT_EVENTS_Deta

NOTE 20 - SUBSEQUENT EVENTS (Detail) (USD $)

12 Months Ended

0 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Mar. 05, 2015

Jan. 15, 2015

Feb. 28, 2015

Nov. 24, 2014

Sep. 24, 2014

Sep. 19, 2014

Aug. 25, 2014

Jul. 21, 2014

Jan. 30, 2015

Jan. 05, 2015

Feb. 02, 2015

Aug. 26, 2014

Sep. 26, 2014

Mar. 13, 2015

Jan. 31, 2015

Jan. 28, 2015

Jan. 25, 2015

Closings

Subsequent Event [Line Items]

Restricted common stock, amount

$0

($15,000)

Proceeds from Convertible Debt

3,475,000

0

0

Fixed conversion rate

$11.75

Number of closings

6

Notes Payable, Other Payables [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

12,434

Convertible notes, interest rate

5.99%

Debt Instrument, Maturity Date

5-May-15

Sixth Closing [Member]

Subsequent Event [Line Items]

Sale of stock, consideration

5,000,000

Common Stock [Member]

Subsequent Event [Line Items]

Sale of stock, shares to be issued

2,463,000

Option One [Member] | First Closing [Member]

Subsequent Event [Line Items]

Sale of stock, consideration

2,000,000

Option One [Member] | Second Closing [Member]

Subsequent Event [Line Items]

Sale of stock, consideration

2,000,000

Option One [Member] | Third Closing [Member]

Subsequent Event [Line Items]

Sale of stock, consideration

2,000,000

Option One [Member] | Fourth Closing [Member]

Subsequent Event [Line Items]

Sale of stock, consideration

2,000,000

Option One [Member] | Fifth Closing [Member]

Subsequent Event [Line Items]

Sale of stock, consideration

2,000,000

Option Two [Member] | First Closing [Member]

Subsequent Event [Line Items]

Sale of stock, consideration

1,000,000

Option Two [Member] | Second Closing [Member]

Subsequent Event [Line Items]

Sale of stock, consideration

1,000,000

Option Two [Member] | Third Closing [Member]

Subsequent Event [Line Items]

Sale of stock, consideration

1,000,000

Option Two [Member] | Fourth Closing [Member]

Subsequent Event [Line Items]

Sale of stock, consideration

1,000,000

Option Two [Member] | Fifth Closing [Member]

Subsequent Event [Line Items]

Sale of stock, consideration

1,000,000

Subsequent Event [Member]

Subsequent Event [Line Items]

Sale of stock, shares to be issued

22,160,000

Sale of stock, consideration

15,000,000

Subsequent Event [Member] | Vaporfection International Inc. [Member]

Subsequent Event [Line Items]

Conversion of warrants, shares

206,480

Subsequent Event [Member] | Notes Payable, Other Payables [Member]

Subsequent Event [Line Items]

Convertible notes, interest rate

18.00%

Notes payable

249,000

Debt Instrument, Maturity Date

1-Jul-15

Debt instrument late charge percentage on principal

5.00%

Subsequent Event [Member] | Restricted Stock [Member] | PVM International Inc. (PVMI) [Member]

Subsequent Event [Line Items]

Sale of stock, consideration

5,000,000

Sale of stock, price per share received

$2

Subsequent Event [Member] | Preferred Stock [Member]

Subsequent Event [Line Items]

Sale of stock, shares to be issued

2,000,000

Subsequent Event [Member] | Common Stock [Member]

Subsequent Event [Line Items]

Sale of stock, shares to be issued

12,160,000

Convertible Debt [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

3,750,000

2,500,000

3,500,000

Proceeds from Convertible Debt

250,000

500,000

1,000,000

1,000,000

1,000,000

Warrant instrument grant agreement, description

The parties also entered into a warrant instrument granting the Investor the right to purchase shares of common stock of the Company equal to the principal amount of the applicable Modified Debenture divided by a price (the "Reference Price") equal to 120% of the last reported closing price of the Common stock on the applicable closing date of the Modified Debenture, at an exercise price equal to the Reference Price, with a three year term.

Exercise price term

The Company also entered into a Debenture Amendment Agreement and an Amended and Restated Debenture for the amount outstanding under the original Debenture, (1) reflecting the terms set forth above, (2) providing for accrued and unpaid interest to be payable upon conversion or maturity rather than on specified payment dates and (3) amending the conversion price of the Debenture to be equal to the lower of $5.00 or 51% of the lowest volume weighted average price for the 20 consecutive trading days prior to the applicable conversion date.

Debenture fee percentage

5.00%

Convertible notes, interest rate

5.00%

10.00%

Conversion price of warrants, description

Beginning four months (as subsequently amended) after the initial closing, the Company will begin making amortization payments on the debt in cash, prompting a 30% premium or, at their option and subject to certain conditions, in shares of common stock valued at 70% of the lowest volume weighted average price of the common stock for the 20 prior trading days. However, in the event the registration statement filed by the Company in connection with the respective purchase agreements is not effective within 120 days of the initial closing date under the July 2014 Purchase Agreement and 120 days of the initial closing date under the September 2014 Purchase Agreement, the July 2014 Purchase Agreement Debenturesb and the September 2014 Purchase Agreement Debenturesb, respectively, conversion rate will be, during the period commencing 120 days after the initial closing date until the registration statement is effective, equal to 63% of the lowest volume weighted average price of the common stock for the 20 prior trading days. If the aforementioned registration statement is not effective within 160 days of the initial closing date, each of the debenturesb conversion rate will be, during the period commencing 160 days after the initial closing date until the registration statement is effective, equal to 60% of the lowest volume weighted average price of the common stock for the 20 prior trading days.

Debt Instrument, Maturity Date

19-Sep-15

21-Jul-15

Convertible Debt [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

1,800,000

1,500,000

Fixed conversion rate

$1.83

$5

Convertible Debt [Member] | Subsequent Event [Member] | Funded at the Closing of the Purchase Agreement Amendment [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

200,000

100,000

Convertible Debt [Member] | Subsequent Event [Member] | Funded within thirty (30) days of the closing [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

100,000

Convertible Debt [Member] | Subsequent Event [Member] | Funded within two days following the filing of a registration statement with the SEC to register the shares underlying the debentures [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

100,000

100,000

Convertible Debt [Member] | Subsequent Event [Member] | Funded within two days of receipt of the first comment letter from the SEC with regard to the Registration Statement [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

100,000

100,000

Convertible Debt [Member] | Subsequent Event [Member] | Funded within two days of the date that the Registration Statement is declared effective by the SEC [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

500,000

1,200,000

Convertible Debt [Member] | Subsequent Event [Member] | Funded within five days of the date that the Registration Statement is declared effective by the SEC [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

500,000

Convertible Debt [Member] | Subsequent Event [Member] | Funded within each of 90, 120, 150, and 180 days from the Closing of the Purchase Agreement Amendment Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

100,000

Convertible Debt [Member] | Subsequent Event [Member] | Funded at the Closing [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

200,000

Convertible Subordinated Debt [Member] | Subsequent Event [Member] | Mr. Ned L. Siegel, the chairman of the Company's Board[Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

50,000

50,000

Convertible notes, interest rate

8.00%

8.00%

Subordinated convertible promissory notes, maturity period

3 years

3 years

Convertible Subordinated Debt [Member] | Subsequent Event [Member] | Mr. Mitchell Lowe, a member of the Board [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

50,000

Convertible notes, interest rate

8.00%

Subordinated convertible promissory notes, maturity period

3 years

Debentures [Member] | Convertible Debt [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

3,000,000

Debt Instrument, Tranche One [Member] | Convertible Debt [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

1,000,000

1,000,000

Proceeds from Convertible Debt

1,000,000

Debt Instrument, Tranche Two [Member] | Convertible Debt [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

1,500,000

1,000,000

Proceeds from Convertible Debt

1,000,000

Debt Instrument, Tranche Three [Member] | Convertible Debt [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

1,000,000

Proceeds from Convertible Debt

500,000

Private Placement [Member] | Subsequent Event [Member] | Minimum [Member]

Subsequent Event [Line Items]

Restricted common stock, amount

$1,000,000

Note Warrant [Member]

Subsequent Event [Line Items]

Warrants exercisable period

5 years

Purchase an amount of Company Common Stock, as a percentage of principal amount of notes

50.00%

Warrants, exercise price as a percentage of conversion price

200.00%

Conversion price of warrants, description

The Conversion Price of the Warrants is either (i) 85% of the volume-weighted average price of the Common Stock for the thirty trading days prior to notice of Conversion or (ii) 85% of the per share price of the Company's next common stock offering of not less than $2 million. Mr. Siegel and Mr. Lowe also received registration rights for the shares underlying the Siegel Notes and the Lowe Notes, respectively.